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PARTI 
CONTINUOUS AMBULATORY PERITONEAL 
DIALYSIS IN CHILDREN 
CAPD IN CHILDREN 
1 GENERAL INTRODUCTION 
R.E. Reddingius, C.H. Schröder, L.A.H. Monnens 
Department of Paediatrics, Sint Radboud University Hospital, Nijmegen, The Netherlands. 
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1.1 PERITONEAL DIALYSIS IN CHILDREN 
Chronic renal failure 
In chronic renal failure the total amount of functioning nephrons has been significantly 
reduced, leading to an impaired excretory function. The excretory function of the kidneys 
is usually estimated from the clearance of creatinine. Symptoms of renal failure, like 
growth retardation, poor weight gain, renal osteodystrophy, hypertension and anaemia, 
usually occur when creatinine clearance is below 25 %. Conservative treatment in the form 
of multiple medications and a restrictive diet can ameliorate these symptoms. When renal 
function drops below 5-10 % the patient will not be able to survive without some form 
of renal replacement therapy. This condition is called endstage renal disease. 
Endstage renal disease is very rare in children. Worldwide incidence rates average 11 
per million children [1]. In the Netherlands an incidence of 6 per million children was 
reported over the period 1979 to 1986 [2]. In the event of end stage renal disease a renal 
transplantation should be the ultimate goal [3-5]. Chronic dialysis has become the bridge 
between conservative treatment and transplantation. There are two major types of chronic 
dialysis: intermittent haemodialysis and continuous ambulatory peritoneal dialysis. 
Haemodialysis is usually performed in the hospital thrice a week. During a period of 
approximately 4 hours, there is an exchange of fluid and solutes between blood and 
dialysate across a semipermeable membrane. Haemodialysis requires an access route to the 
circulatory system. In young children the creation of a suitable arteriovenous fistula, 
allowing sufficient blood flow, may be difficult. 
Peritoneal dialysis 
In 1923 Ganter described the intermittent infusion of saline solution into the peritoneal 
cavity of a uraemic guinea pig [6]. The urea concentration of the drained solution was 
equal to the blood concentration. He concluded that the peritoneum could be used as a 
membrane to remove toxic substances from the body. In the years that followed, peritoneal 
dialysis was used in an attempt to treat uraemic patients. Data concerning 101 patients 
treated with peritoneal dialysis between 1923 and 1948 were published in 1950 [7]. Sixty 
three of these patients had reversible renal diseases and 32 of them recovered. After 1950 
peritoneal dialysis became an accepted treatment for acute renal failure in adults [8]. The 
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first reports on the use of the peritoneum to treat a child with renal failure appeared in 
1948 and 1949 [9,10]. In 1961 the use of temporary peritoneal dialysis in acute renal 
failure in children had become a standard treatment modality [11,12]. In 1962 chronic 
intermittent peritoneal dialysis was started to be used in adults for the treatment of chronic 
renal failure. However, infectious complications limited the long-term use of this method. 
Chronic peritoneal dialysis was successful when access to the peritoneal cavity was created 
by repeated puncture for each dialysis session [13,14]. Following the development of a 
silicone rubber peritoneal catheter with two dacron cuffs by Tenckhoff, the use of chronic 
intermittent peritoneal dialysis increased significantly [15]. In 1978 first experiences with 
the treatment of chronic renal failure by means of a new peritoneal dialysis technique in 
adults were published by Popovich et al. [16]. The principle of this technique was, that 
dialysate was now continuously present in the peritoneal cavity, while the patient 
conducted his normal activities. The dialysis solution was changed 5 times per day, 7 days 
per week. This method, called continuous ambulatory peritoneal dialysis (CAPD), was 
subsequently used in children [17]. A few years later CAPD was also applied in adults 
[18] and children [19] in the Netherlands. From 1980 onwards thousands of children have 
been successfully treated with CAPD [20]. At the end of the eighties, the contribution of 
CAPD to the treatment of endstage renal disease in children varied from 10 % to 75 % 
between countries around the world [20-22]. The number of young children with endstage 
renal disease treated with renal replacement therapy has increased since the introduction 
of CAPD [23]. Even the use of this dialysis modality in babies has proven to be effective 
[24,25]. 
CAPD in children 
During CAPD the peritoneal membrane is used as a semipermeable membrane. To gain 
access to this membrane, a catheter is surgically inserted into the abdominal cavity (see 
figure 1). Small catheters are available for paediatric patients. An especially designed 
dialysis fluid, which is usually exchanged 4 times per day, is continuously present in the 
abdomen. The dialysate usually contains glucose as an osmotic agent. The concentration 
of glucose can be altered, depending on the amount of fluid which has to be removed from 
the body. The inflow and outflow of fluid is by force of gravity. Specialised coupling 
equipment is used to connect the bags with dialysate to the catheter line to minimise 
infectious complications. In the paediatric dialysis centre in Nijmegen the Netherlands a 
coupling device using ultraviolet light, the so called UV-flash system, is used [26]. 
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Figure 1. The catheter in the peritoneal cavity during CAPD. 
Continuous cycling peritoneal dialysis (CCPD) is a modification of CAPD, which can 
also be used in children [27,28]. During CCPD dialysis is performed by a machine (the 
cycler) during the night. There are many differences between CAPD and CCPD and the 
reasons to choose for one or another treatment modality are numerous [29]. Sometimes 
children may have a poor appetite during CAPD treatment, because of the fact that the 
abdomen is filled with fluid and/or because large amounts of glucose are continuously 
absorbed from the dialysate. This may be a reason to switch from CAPD to nightly 
intermittent CCPD (NIPD), leaving the abdomen empty during the day [30]. Because 
dwell times during CCPD are much shorter and maximum fluid removal takes place at the 
beginning of a dwell, CCPD can also be used when it is difficult to remove a sufficient 
amount of water from the body. 
Patients with endstage renal disease can be maintained on CAPD for a long period, 
awaiting transplantation [31]. Middle molecules, molecules with a molecular weight 
ranging from 300 tot 12,000 dalton, are removed more efficiently by CAPD in comparison 
to haemodialysis [32]. The removal of toxins in a patient treated by CAPD however is still 
not nearly as effective as in a person with normal kidney function. Patients on CAPD, 
even those with a protein restricted diet, usually have blood urea nitrogen levels above 20 
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mmol/1 (reference range 2-7 mmol/1). Various medications are often necessary to control 
mineral status and blood pressure. Similar to patients on haemodialysis, erythropoietin has 
to be administered in most cases to correct renal anaemia [33,34] and growth hormone has 
to be given to acquire normal growth [35]. 
In young children С APD has a number of advantages over haemodialysis. An important 
advantage is the fact that an arteriovenous fistula, with all its potential complications, is 
not needed. Because of this the number of invasive procedures is also less. In contrast to 
haemodialysis, the blood levels of various substances are steady after a few weeks of 
treatment by CAPD because there is a constant removal of waste products from the body. 
For this reason the disequilibrium syndrome, caused by the rather sudden changes in body 
composition during intermittent haemodialysis, does not occur during CAPD. Since 
treatment is performed by the parents at home, school attendance and family life is more 
normal during CAPD [36]. 
Contraindications can be of medical or psychosocial nature. Effective dialysis is not 
possible if there are severe adhesions in the peritoneal cavity. Since the treatment is 
performed at home, CAPD can only be successful if the caretakers of the child can cope. 
In adolescents CAPD can be contraindicated because the presence of a catheter in the 
abdomen can contribute to the development of a negative self esteem. 
Peritonitis is an important complication of CAPD. The presence of a catheter, creating 
access to the peritoneal cavity, in combination with reduced peritoneal defence 
mechanisms are responsible [37]. Peritonitis can be preceded by another infectious compli­
cation causing significant morbidity, the so-called tunnel and/or exit site infection [38]. 
The reported frequency of peritonitis in children is between once every 3.5 and once every 
10.5 treatment months [26,39-42]. In the paediatric dialysis centre in Nijmegen the Nether­
lands the peritonitis incidence decreased from one episode every 6.7 months in the period 
1980-1987 to one episode every 20 months in the period 1987-1990 [26]. The introduction 
of the UV-flash system in 1987 was assumed to have had a positive effect. A peritonitis 
incidence of once every 27.7 months was recently reported in adults, with the application 
of this system [43]. With the use of other connection systems, such as the so called 
Y-connector system, low peritonitis rates have also been reported in adult patients [44]. 
A high mortality in relation to peritonitis has never been reported in paediatric studies, 
although peritonitis is the direct cause of death in 7 to 10 % of adult patients [45]. A 
peritonitis in a CAPD patient can usually be treated effectively by intraperitoneal 
administration of antibiotics [46]. Peritonitis can however cause alterations in the 
peritoneal membrane impairing its function, sometimes even leading to CAPD failure [47, 
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48]. Other frequent complications, such as hernias of the abdominal wall, are related to 
the increased intraperitoneal pressure [26,49,50]. 
1.2 FLUID KINETICS IN CHILDREN ON CAPD 
Ultrafiltration 
The kidneys play an important role in the maintenance of water balance. In patients with 
end stage renal disease there is generally a clinical requirement to remove excess water 
from the body. During haemodialysis fluid can be ultrafiltered across the membrane of the 
artificial kidney by applying a difference in hydrostatic pressure. During peritoneal 
dialysis, fluid can be removed from the body by creating a difference in osmotic pressure 
between dialysis solution and blood. The standard solute applied as an osmotic agent is 
glucose. Although it is a process of osmosis rather than ultrafiltration, the removal of fluid 
during CAPD is called (net) ultrafiltration. 
Д оІшпе 
transcapillary ultrafiltration 
Time 
Figure 2. Loss of ultrafiltration as a result of lymphatic absorption. 
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Net ultrafiltration refers to the amount of fluid drained from the patient minus the 
amount instilled. This net transport of fluid equals the difference between osmotically 
driven water transport into the cavity, called transcapillary ultrafiltration, and fluid loss 
from the cavity, caused by lymphatic absorption (see figure 2) [51]. The transcapillary 
ultrafiltration rate is at its maximum at the beginning of the dwell, because the osmotic 
pressure difference between blood and dialysate is maximal. Lymphatic absorption is 
thought to be a rather linear process [52]. 
Clinical experience suggested that adequate ultrafiltration is more difficult to achieve 
in infants and young children [53]. The relatively large peritoneal surface area in relation 
to dwell volume [54] and the more rapid resorption of glucose from the dialysate [53,55, 
56], with a decrease of osmosis as a consequence, were proposed as possible causes. 
Another possibility, an increased loss of fluid from the peritoneal cavity due to a high 
lymphatic absorption rate, has also been suggested [57]. 
Lymphatic absorption 
Fluid introduced in the peritoneal cavity is absorbed by the peritoneal cavity lymphatics 
[58]. In fact even red blood cells and latex particles are resorbed via the peritoneal 
lymphatics [59,60]. The absorptive capacity of the peritoneal cavity lymphatics has been 
used effectively for many years to perform intraperitoneal blood transfusions in the fetus 
[61-63]. 
A significant amount of fluid is drained from the peritoneal cavity via specialized end 
lymphatic openings, called stornata, located in the subdiaphragmatic peritoneum [64]. 
Electron microscopy studies have shown that the stornata permit absorption of intraperito-
neal particles, cells, colloids and fluid into the underlying lymphatic lacunae via 
extracellular pathways (see figure 3) [60]. Absorption takes place as a result of the 
excursions of the diaphragm during respiration [65]. As the diaphragm relaxes during 
expiration intraperitoneal fluid enters the lacunae. During inspiration the contraction of the 
diaphragm causes closure of the stornata, while the content of the lacunae is emptied into 
efferent lymphatics at the same time. 
Under controlled conditions absorption of fluid and proteins from the peritoneal cavity 
seems rather constant [66]. However, lymphatic absorption is raised in response to an 
increased intraperitoneal pressure [67] or respiratory rate [58]. Upright posture reduces 
lymphatic absorption, presumably because there is less contact between the diaphragm and 
the fluid in the peritoneal cavity [68]. 
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mesothelium PERITONEAL CAVITY 
Figure 3. Diagram of a stoma, linking the peritoneal cavity with the lumen of a lymphatic 
lacuna. 
The lymphatics draining the peritoneal cavity serve as a oneway system returning excess 
intraperitoneal fluid, protein, particles and bacteria to the circulation. Although normally 
beneficial, lymphatic absorption has some adverse effects on the clinical application of 
peritoneal dialysis. An important negative effect of lymphatic absorption is that it reduces 
net ultrafiltration. Part of the fluid that has entered the peritoneal cavity because of 
osmosis is directly returned to the blood by lymphatic absorption. Solute clearances are 
also impeded, because toxins like urea are likewise returned to the systemic circulation by 
lymphatic absorption. 
Alternative, less absorbable osmotic agents have been sought in order to achieve a more 
sustained influx of water during a dialysis session. Lymphatic absorption has hindered 
their development, since intraperitoneally administered substances like glucose polymers, 
will be resorbed by the lymphatics and can have systemic toxic effects [69]. 
A potential beneficial effect of lymphatic absorption is their role in the killing of 
bacteria in the peritoneal cavity, but very little is known on this subject. Another 
advantage is the fact that as a result of lymphatic absorption, adequate serum levels of 
certain drugs can be accomplished after intraperitoneal administration [70,71]. Intraperito-
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neal administration of recombinant human erythropoietin has been shown to be effective 
in the treatment of renal anaemia [72]. 
Measurement of lymphatic flow 
Unfortunately, there is no method available for direct measurements of the lymphatic 
absorption of fluid and solutes from the peritoneal cavity during peritoneal dialysis. 
Cannulation of lymphatic ducts draining the peritoneal cavity in experimental animals is 
only partially possible [73]. 
If isotonic fluid is absorbed from the peritoneal cavity there is no change of the intra-
peritoneal protein concentration [67]. The fractional resorption rates of fluid and protein 
are unaffected by the protein concentration within the peritoneal cavity [66]. The 
disappearance of macromolecules from the peritoneal cavity is not dependent on molecular 
size [74] and macromolecules appear in the blood at the same time after intraperitoneal 
administration, irrespective of their molecular weight [75]. Apparently intraperitoneal fluid 
is drained by the peritoneal lymphatics without an increase or decrease of protein 
concentration. Nolph et al. showed that protein moved out of the peritoneal cavity at the 
same rate whether the dialysis solution was isotonic or hypertonic [52]. Since the massive 
influx of fluid into the cavity, caused by the hypertonic solution, did not slow down the 
protein removal from the cavity, it was assumed that proteins are in fact removed from 
the peritoneal cavity exclusively by lymphatics. 
Direct absorption from the peritoneal cavity into the capillaries of macromolecules with 
a molecular weight greater than 20,000 is minimal [75]. After unidirectional transport from 
capillaries into the peritoneal cavity, proteins such as albumin are transported back to the 
venous circulation by the lymphatics. This is also referred to as the two-compartment 
model (see figure 4) [76]. 
Since intraperitoneal marker proteins are returned to the circulation exclusively by the 
lymphatics and since intraperitoneal fluid is drained without sieving of the marker it was 
concluded that lymphatic absorption can be approximated from the appearance rate of an 
intraperitoneally administered marker protein in the blood or from the disappearance rate 
of such a marker from the peritoneal cavity [51]. 
Lymphatic absorption can be estimated from the appearance rate of an intraperitoneally 
administered radio-labelled colloid using the following formula, where LA is the total 
lymphatic flow during the time of the study, VD is the volume of distribution of the tracer, 
ACD is the rise in plasma concentration of the tracer colloid and Cp is the time averaged 
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Figure 4. The two-compartment model. 
mean intraperitoneal concentration of the tracer: 
LA-^L x ДС„ 
О) 
A study in adults on CAPD yielded a lymphatic absorption rate of approximately 21 
ml/h [77]. Disadvantages of the method are, that a radioactive tracer must be used and that 
multiple bloodsampling is necessary. Therefore studies in children on CAPD have never 
been performed. 
For the estimation of lymphatic absorption using tracer disappearance rates formula (2) 
can be used, where V0 and V, are intraperitoneal fluid volumes at the beginning and the 
end of the dwell and where C0 and C, are intraperitoneal tracer concentrations at the 
beginning and the end of the dwell. In order to be able to determine V0 and V„ residual 
volume has to be known, which can be calculated in a number of ways, preferably from 
the dilution of the intraperitoneally administered marker [78]. 
M = (V0XC0) - (VCXCC) (2) 
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This method can be accomplished relatively simple in the clinical setting and has been 
applied in patients on CAPD [57,79-83]. Albumin, mI-albumin, autologous haemoglobin 
and dextran 70 were used as marker proteins. In these studies lymphatic absorption ranged 
from 8 to 126 in adults on CAPD. Mactier performed a study, using albumin as a marker, 
in which adults and children were compared [57]. Values for lymphatic absorption were 
much higher in children than in adults in relation to body weight and body surface area. 
The difference between tracer appearance and disappearance rate 
Some studies have been performed measuring the disappearance of a radioactive tracer 
from the peritoneal cavity and the appearance in blood simultaneously in experimental 
animals [84-86], patients on CAPD [77] and patients with ascites [87]. The data demon-
strated that only 5 to 58 % of the marker that disappeared from the peritoneal cavity, 
appeared in the plasma. Apparently loss of proteins from the peritoneal cavity does not 
equal uptake by the blood. 
Theoretically the tracer disappearance method can give rise to an overestimation of 
lymphatic absorption when the marker is trapped in the tissues surrounding the peritoneal 
cavity. Struijk et al. performed a study addressing this problem [88]. Lymphatic absorption 
was estimated in adults on CAPD from the disappearance rate of dextran 70 on day 1 and 
day 3. The marker was administrated intraperitoneally continuously in the period between 
the two test dwells, presumably saturating the tissues with dextran 70. Since the lymphatic 
absorption rate did not change, it was concluded that trapping of the marker was of no 
importance. 
However, studies in rats have demonstrated that proteins are directly transported from 
the peritoneal cavity into the surrounding interstitium [84,89]. In one of these studies 
disappearance rates and appearance rates were both measured using labelled fibrinogen 
[84]. Most of the fibrinogen which had been transferred from the cavity but had not 
arrived in the blood was found in the surrounding tissues, especially in the anterior 
abdominal wall. Measurements of tissue concentration profiles of serum albumin absorbed 
from the peritoneal cavity have demonstrated that a hydrostatic pressure driven convection 
is the most likely underlying mechanism [89]. 
The capillary, the interstitium and the mesothelium are the major elements of the 
peritoneal membrane from a physiological viewpoint (see figure 5) [90]. As opposed to 
the mesothelium, the interstitium presents a significant barrier to the transport of protein. 
Protein transport from the interstitium into the blood capillary is very restricted [91]. The 
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Figure 5. The peritoneal membrane. 
major route for removal of protein from the interstitium is the intratissue lymphatic 
capillary. 
The two compartment model discussed earlier can be adapted to a three compartment 
model, including the peritoneal tissue space (see figure 6) [76]. According to this model, 
fluid is transported from the cavity by the subdiaphragmatic lymphatics directly into the 
blood or by hydrostatic pressure driven convection into the tissue. 
If protein transport from the peritoneal cavity is primarily convective, then a fluid flux 
into the cavity during dialysis with a hypertonic solution would be expected to decrease 
protein transport. As noted earlier, Nolph et al. observed that albumin was removed from 
the peritoneal cavity in rats during a hypertonic dialysis at the same rate as during an 
isotonic dialysis [52]. This finding was confirmed later in studies by Flessner et al. using 
labelled immunoglobulin G [85]. In this latter study the appearance rate in blood, which 
was simultaneously measured, was also unaffected by the hypertonicity of the dialysis 
solution. The appearance rate in plasma was approximately 20 % of the disappearance rate 
from the peritoneal cavity with isotonic and hypertonic dialysis solution. The tissue 
concentration profiles of labelled IgG were also similar with both solutions [92]. 
Apparently there are two relatively independent convective processes occurring during 
hypertonic dialysis, which move fluid in opposite directions. There is a hydrostatic 
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Figure 6. The three-compartment model. 
pressure driven flux of fluid and solutes into the tissue and an osmotically driven flux into 
the cavity. Flessner has hypothesized that relatively large gaps between mesothelial cells 
exist in some areas of the peritoneum, permitting influx of fluid and solutes into the tissue 
by force of hydrostatic pressure, whereas an osmotically driven influx of fluid takes place 
in the vicinity of superficial blood capillaries [76]. 
It emerges from the above that the disappearance rate of intraperitoneally administered 
macromolecules does not equal flow through subdiaphragmatic lymphatics, but estimates 
total lymph loss [93]. Appearance rates in blood are much lower because at the end of a 
dwell a substantial amount of marker is still in the tissue compartment. This is in 
accordance with the results of a study by Tran et al., in which lymph flow estimated from 
indwelling lymphatic catheters was compared to calculations of lymphatic drainage by the 
appearance of tracer in the blood and the disappearance of tracer from the peritoneal 
cavity [86]. The tracer disappearance method yielded the highest results, whereas the 
results where lowest with the direct cannulation technique. The lymph flow rates estimated 
from the indwelling catheters was approximately 10 % of tracer disappearance rates in 
anaesthetized sheep and approximately 50 % of tracer disappearance rates in conscious 
sheep. This would imply that in conscious animals subdiaphragmatic lymphatics are 
responsible for only half of total lymphatic fluid uptake from the peritoneal cavity. 
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It must be noted that the disappearance rate is not a measure for total fluid loss, because 
fluid loss as a result of an osmotic pressure gradient will not be associated with loss of 
macromolecules. In fact, if a hypotonic dialysis solution is applied, fluid is lost from the 
peritoneal cavity because of osmotic pressure driven transcapillary backfiltration [94]. 
The tracer disappearance method seems to be the best available approximation in the 
clinical setting of total lymphatic absorption from the peritoneal cavity during CAPD. To 
prevent misunderstandings it might be advisable to use the term marker clearance instead 
of lymphatic absorption, when tracer disappearance is used to measure marker related fluid 
loss from the peritoneal cavity in CAPD patients. 
Transcapillary ultrafiltration 
Transcapillary ultrafiltration (TCUF) can be estimated from the dilution of an intraperito-
neally administered marker [83]. The following formula can be applied, where C0 and C, 
are intraperitoneal tracer concentrations at the beginning and the end of the dwell and 
where V0 is the initial intraperitoneal volume: 
TCUF = 3 - X v0 - v0 (3) 
In this formula the total amount of marker (C0 χ V0) is divided by the marker concentra­
tion. In fact this is not entirely correct, because the total amount of marker diminishes 
during the dwell as a result of lymphatic absorption. The following formula is more 
accurate, where MC (marker clearance) is total lymphatic absorption, using the tracer 
disappearance method, and Cp is the time averaged mean intraperitoneal concentration of 
the marker: 
(C- X VJ - (MC X CJ , . . 
TCUF = —? ° £- - v0 (4) 
In this formula it is assumed that marker clearance is a linear process, which is supported 
by the observation that fluid and protein absorption from the peritoneal cavity is relatively 
constant [52,66]. However, as discussed earlier, many factors can influence lymphatic 
absorption. In fact variability of marker clearance during a peritoneal dialysis session was 
observed by Breborowicz et al. in rabbits [95]. 
Since transcapillary ultrafiltration is not linear during the dwell, it is necessary to take 
several samples of dialysate in order to be able to reconstruct a transcapillary ultrafiltration 
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curve. Loss of fluid, because of sampling will have to be taken into account. The 
arithmetic becomes more complicated, although it remains essentially the same. In small 
children sampling can be a problem, because it can significantly influence dwell volume. 
Comparison of data between adults and children 
When fluid kinetics, measured for a specific patient at a specific moment, are compared 
to results of measurements of another patient or even of the same patient at another 
moment, there are many factors that have to be taken into account. The duration of the 
dwell, the characteristics of the used dialysis solution, the kind of fluid marker used and 
the clinical condition are obviously of importance, but these items can be standardized. It 
is more difficult to standardize or correct for the size of the patient. Not only the results 
of the estimations of lymphatic absorption and transcapillary ultrafiltration have to be 
corrected in some way or another, but also dwell volume. 
Esperanca and Collins measured the peritoneal surface area in unfixed postmortem 
material of 6 adults and 6 children [96]. The peritoneal surface area was related to body 
surface area and not to body weight. In fact, greater mass transfer area coefficients in 
children in relation to body weight reflect an increased effective peritoneal surface area 
in comparison to adults [97]. It thus seems logical to relate fluid kinetics to body surface 
area and not to body weight. 
For the treatment of adults on CAPD a dwell volume of 2000 ml is usually applied, 
whereas a dwell volume of approximately 40 ml/kg is advised in paediatric patients. In 
paediatrics it seems logical to relate dwell volume to body weight, because the content of 
the peritoneal cavity is related to body weight. The fact that small things, like the 
abdomen of a small child have a relatively low content in relation to surface area is illus-
trated in figure 7. One would assume that an intraperitoneal volume of 2000 ml/1.73 m2, 
which would be similar to adults, would not be tolerated in young children. However, in 
a study by Fischbach et al. the intraperitoneal pressure was measured using a dwell volume 
of 1000 ml/m2 and was found to be relatively low in infants below the age of one year 
[98]. 
The relatively low dwell volume in relation to peritoneal surface area could impede 
ultrafiltration in young children [54]. This would be a reason to relate dwell volume to 
body surface area, when studies are being done to compare individuals of different ages 
and sizes. This was recently confirmed in a study by Kohaut et al., who found that urea 
and glucose equilibration was more rapid in young children, when dwell volume was 30 
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Figure 7. Illustration of the fact that small things, like the abdomen of a small child, have a 
relatively low content in relation to surface area. 
ml/kg, whereas urea and glucose equilibration curves were similar in children of different 
ages when dwell volume was 1200 ml/m2 [99]. At the present time dwell volume is still 
usually calculated from body weight in the clinical setting. If, for this reason, dwell 
volume is related to body weight in a study on fluid kinetics in children on CAPD, the 
fact that dwell volume is relatively low in relation to peritoneal surface area in young 
children should be taken into account when the results are interpreted. 
1.3 INTRAPERITONEAL ADMINISTRATION OF ERYTHROPOIETIN IN 
CHILDREN TREATED WITH CAPD 
Erythropoietin 
The idea of the existence of a humoral factor controlling erythropoiesis originated 
approximately 100 years ago [100]. Definite evidence for the existence of erythropoietin 
was provided by Erslev in 1953 [101]. He demonstrated the occurrence of reticulocytosis 
and, in the long term, increased haematocrit levels in rabbits, who were given plasma from 
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severely anaemic donor rabbits. In fact, he predicted the potential therapeutic value of the 
hormone once available in purified form. 
In 1977 purification of the hormone from human urine was accomplished by Miyake 
et al. [102] and the gene for human erythropoietin was cloned in 1985 [103,104]. Mass 
production of erythropoietin by recombinant DNA technology subsequently became 
possible. 
Recently some excellent reviews have been written on the physiology of erythropoietin 
[100,105-111]. Erythropoietin is a glycoprotein with a molecular weight of approximately 
30 kD, with a carbohydrate portion of 40 %. Hypoxia is the primary stimulus for 
erythropoietin production. The hormone is produced primarily by a fibroblast-like cell 
population in the cortical interstitium of the kidney. However, in anephrics a significant 
amount of erythropoietin can be produced at extrarenal sites [112]. The hormone induces 
proliferation and differentiation of erythroid progenitor cells in the bone marrow and the 
resultant increase in circulating red blood cells alleviates the hypoxic stress. 
Before pure erythropoietin became available, an in vivo bioassay in mice was most 
commonly used to measure erythropoietin. Today immunological assays are available [113, 
114]. The plasma steady state concentration of erythropoietin in healthy individuals is in 
the range from 4 to 30 mU/ml. Levels do not seem to be different in children [115]. 
Erythropoietin levels have to be judged in relation to haemoglobin levels. In uncompli-
cated anaemias, such as iron deficiency anaemia, there is an inverse relationship between 
the two. 
In some diseases the production of erythropoietin is deficient. In these cases treatment 
with recombinant human erythropoietin may be beneficial. The use of erythropoietin for 
the correction of anaemia in patients with renal disease is well established [116]. The 
application of the hormone in other conditions, such as cancer [117], rheumatoid arthritis 
[118], AIDS [119], prematurity [120], and the prophylactic administration in the 
perisurgical setting [121] are still being explored. 
Renal anaemia 
Anaemia in patients with chronic renal failure is an important clinical problem, affecting 
over 90 % of patients with endstage renal disease. The anaemia is the result of a decreased 
production of erythropoietin [122], a decreased red blood cell survival [123] and a 
decreased response to erythropoietin [124]. Other contributing factors may be iron or 
folate deficiency, aluminium toxicity, osteitis fibrosa cystica and occult blood loss [125]. 
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The primary cause is a diminished production of erythropoietin by the damaged kidney. 
Although erythropoietin levels are normal in patients with endstage renal disease, they are 
inappropriately low for the degree of anaemia [126,127]. It is not clear why erythropoietin 
production is inappropriate in chronic renal failure [128]. There is evidence that the ability 
of the diseased kidney to produce erythropoietin is not simply lost. It rather seems that the 
regulation of erythropoietin secretion is disturbed. 
In patients with endstage renal disease, anaemia can improve after institution of dialysis. 
In comparison to patients on hacmodialysis, anaemia is less severe in patients treated by 
CAPD [34]. Chandra et al. found significantly higher erythropoietin levels in patients on 
CAPD in comparison to patients on haemodialysis [129,130]. This has been attributed to 
a better removal of uraemic toxins, an improved protein metabolism and the production 
of erythropoietin by peritoneal macrophages [34]. 
For children the consequences of renal anaemia are very severe [33]. Anaemia 
significantly influences the general condition of the child, inhibits normal social 
interactions and possibly even damages psychosocial development. Before erythropoietin 
became available, almost all paediatric dialysis patients were dependent on regular transfu-
sions. Multiple transfusions carry the risk of transmission of infections and can cause iron 
overload. It can also induce sensitization to histocompatibility antigens in these kidney 
transplantation candidates. 
The therapeutic efficacy of recombinant human erythropoietin in the treatment of renal 
anaemia was first published in 1986 by Winearls et al. in a group of haemodialysis 
patients [131]. Erythropoietin was administered intravenously thrice weekly after each 
dialysis. In a period of only 12 weeks haemoglobin levels increased with an average of 
2.5 mmol/1 and transfusion dependency was completely abolished in all patients. Since 
1986 the clinical efficacy of the treatment of renal anaemia with recombinant human 
erythropoietin has been confirmed in many studies. Side effects of erythropoietin 
treatment, like hypertension, seizures and vascular thrombotic events, are unusual [132, 
133]. They can be attributed primarily to the rapid correction of anaemia and not to 
erythropoietin itself. 
Treatment of renal anaemia in CAPD patients 
The first report on the use of recombinant human erythropoietin in paediatric patients with 
chronic renal failure was published in 1989 by Sinai-Trieman et al. [134]. They successful-
ly treated 5 CCPD patients, aged 12 to 18 years, by subcutaneous administration of 
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erythropoietin thrice weekly. Subsequently other publications on the treatment of children 
with preterminal renal failure [135,136], children on peritoneal dialysis [135,137-146] and 
children on haemodialysis [135,138,145,147,148] followed. These studies all confirmed 
that erythropoietin therapy in chronic renal failure is effective and safe. 
Different routes of administration are possible. Erythropoietin can be administered 
intravenously, subcutaneously and, in CAPD patients, intraperitoneally. Studies in adults 
have demonstrated that the subcutaneous route is most efficient, with doses of 100 to 150 
units/kg per week [34,149]. In the studies performed in children mean maintenance dosage 
was between 138 and 289 after intravenous administration [135,144,147,148], and between 
74 and 210 units/kg per week, when erythropoietin was administered subcutaneously [134, 
136,137,139,140,143,146]. The hormone can be administered once, twice or thrice a week. 
Ongkingco recently reported that during the maintenance phase of erythropoietin therapy, 
dosing once-weekly is as effective as thrice-weekly in children on CCPD [143]. 
In children there seems to be an influence of age on the dosage needed. In a multicentre 
study by Scigalla et al. in children on haemodialysis, erythropoietin was administered 
intravenously and dosage was 321 units/kg per week in children with an age up to 5 years, 
230 units/kg per week in children between 5 and 10 years and 158 units/kg per week in 
children between 10 and 15 years old [144]. This was confirmed in a similar study by Van 
Damme-Lombaerts et al., establishing a maintenance dose of 225 units/kg per week in 
children with a body weight of less than 30 kg and a maintenance dose of 107 units/kg 
per week in children with a higher body weight [148]. This difference was still apparent 
when patients were grouped according to body surface area (3,938 U/m2 per week for 
patients of 1 m2 or more and 6,493 U/m2 for patients less than 1 m2). 
Subcutaneous administration of erythropoietin, especially of epoetin α (Eprex®, Cilag, 
Herentals, Belgium), is painful [150-153]. The citrate buffer in the vehicle for epoetin α 
was identified as the pain causing factor [154]. Addition of a substance with local 
anaesthetic properties and a reduction of the volume of the vehicle were reported to reduce 
pain [155]. Discomfort can also be reduced by application of local anaesthetic cream 
(Ernia) prior to the injection [152] or by mixing erythropoietin with lidocaine [156]. In 
children treated with CAPD the parents will usually have to perform the injections. The 
amount of stress experienced by the parents of a child treated with CAPD, is determined 
to a great extent to factors related to the CAPD treatment itself, such as blood drawing and 
the administration of medication [157]. 
Intraperitoneal administration of erythropoietin is an alternative mode of treatment in 
patients treated with CAPD. As mentioned in the chapter on fluid kinetics, any substance 
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Figure 8. The complement system. 
added to the dialysate will be removed from the peritoneal cavity by the subdiaphragmatic 
lymphatics and the intratissue lymphatics surrounding the peritoneal cavity. Pharmaco­
kinetic studies have established, that erythropoietin is resorbed from the peritoneal cavity 
of experimental animals [158], adult CAPD patients [159-164] and children on CAPD 
[165]. The bioavailability of intraperitoneally administrated erythropoietin is greatly 
improved when erythropoietin is given undiluted [160]. Some therapeutic studies in adult 
patients have established that erythropoietin is in fact an effective treatment modality [166-
168]. A study in children was broken off because of a high peritonitis rate [141]. 
1.4 THE COMPLEMENT SYSTEM IN CHILDREN TREATED WITH CAPD 
The complement system 
The complement system is an important component of the immune system. Complement 
activation is associated with the production of anaphylatoxins, important mediators of 
inflammation, it participates in the elimination of immune complexes, it helps to neutralize 
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viruses and it plays an important role in the opsonization and killing of bacteria [169]. 
Complement consists of many proteins, which are present in plasma in an inactive form. 
Activation of the complement system leads to the recruitment of these precursor proteins 
into a sequentially proceeding cascade. 
Complement can be activated by two distinct routes, the classical and the alternative 
pathways (see figure 8) [170]. The component C3 plays a central role in the system being 
common to both pathways. Components C5-C9 are designated the terminal components, 
forming the membrane attack pathway, which is also common to both pathways and which 
is responsible for target cell damage and lysis. 
The classical pathway is initiated by binding of CI to antigen-antibody complexes. 
Subsequently, activated CI cleaves C4 in C4a, an anaphylatoxin, and C4b. Activated CI 
also cleaves C2 into two fragments, C2a and C2b. The efficiency of cleavage is greatly 
enhanced when C2 is bound to an adjacent C4b molecule. The C4b,2a complex, the so 
called classical C3 convertase, cleaves C3 producing C3a, which is also an important 
anaphylatoxin, and C3b. 
Foreign surfaces, such as bacterial cell walls, can activate complement via the 
alternative pathway, in the absence of specific antibody. An essential component of the 
alternative pathway C3 convertase is activated C3 itself. Activation of C3 occurs as a 
result of spontaneous hydrolysis. The C3(H20) molecule, which is functionally similar to 
C3b, binds to factor B. Subsequently, factor В is cleaved by factor D, leaving the Bb 
fragment attached to C3(H20), forming C3(H20),Bb. This complex cleaves C3 in precisely 
the same way as the C4b,2a complex of the classical pathway. C3b formed this way is 
continuously deposited on the surfaces of particles or organisms. Whether activation of the 
pathway continues is determined by the properties of the surface. Bound to activating 
surfaces, C3b is protected from inactivating proteins, such as factor H. On these surfaces 
C3b binds factor B, rendering factor В susceptible to cleavage by factor D, resulting in 
the formation of C3b,Bb, which can cleave more C3. Factor P, or properdin, a control 
protein unique to the alternative pathway, stabilizes the C3b,Bb complex. 
The C3b molecule acts as an acceptor of C5, rendering it susceptible to cleavage by the 
C4b,2a complex of the classical pathway, or the C3b,Bb complex of the alternative 
pathway. A fragment of C5, the anaphylatoxin C5a, is released, leaving C5b bound to 
C3b. The membrane attack pathway, which begins with the formation of C5b, proceeds 
via the sequential assembly of C5b, C6, C7, C8 and C9 into a complex with the capacity 
to damage cell membranes. 
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Different laboratory techniques are available for the determination of complement 
function and activation [171]. The CH50 and AP50 are functional assays that determine 
the overall ability of serum to lyse erythrocytes via respectively the classical pathway or 
the alternative pathway. Low levels indicate a deficiency of one or more factors of either 
pathway. Deficiency can be the result of an abnormal or absent synthesis or of 
consumption as a result of complement activation. Individual complement components may 
be quantitated by functional haemolytic assays or by immunochemical methods. The 
estimation of complement fragments, such as the cleavage product C3d, is the most 
sensitive way to establish complement activation. 
CAPD and the complement system 
Some children on CAPD suffer from repeated episodes of peritonitis, while others never 
develop this complication [39]. Differences in the ability of individual subjects to resist 
infection, in other words, differences in host defence, are probably at least partly respon­
sible. A poor general clinical conditionna specific disease of the immune system and the 
application of immunosuppressive therapy can obviously diminish resistance to infection 
in an individual patient. However, children on CAPD generally have no significant 
impairment of systemic immunity [172]. An impaired host defense, locally in the 
peritoneal cavity, may predispose patients treated by CAPD to peritonitis [173]. Changes 
in cellular as well as humoral defence mechanisms in the peritoneal cavity occur during 
CAPD [174,175]. Complement and immunoglobulin together form the basis of humoral 
immunity. Complement factors are important for opsonization and killing of bacteria 
entering the peritoneal cavity during CAPD [176,177]. A decreased opsonic activity of 
peritoneal fluid is related to a high peritonitis rate [178,179]. 
Proteins, for example complement factors, can enter the peritoneal cavity during CAPD 
by means of plasma to dialysate transport. Another potential source of proteins in 
peritoneal dialysate is their local production in the peritoneal cavity itself or in the tissues 
surrounding the cavity [180]. That complement factors could be produced locally is 
supported by the fact that peritoneal macrophages have been reported to produce the 
complement factors C2, C3, C4, B, D and Ρ in vitro [181-186]. 
During CAPD proteins are lost because they are continuously removed from the body 
with the dialysis solution. In adults peritoneal protein loss averages 5 to 10 grams per day 
in stable patients [187,188]. Daily protein loss was reported to be 0.2 to 0.3 g/kg in 
children treated with CAPD [53,189,190]. For the transport from the circulation to the 
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peritoneal cavity, plasma proteins have to pass the endothelium, the interstitium and the 
mesothelial layer. The interstitium, and most of all the capillary endothelium represent 
important barriers for protein transport [90]. Overall protein loss is related to a number 
of factors, such as dwell time, peritoneal permeability and dialysate volume. The concen-
tration of a specific protein in the dialysate is also related to its serum concentration and 
its molecular weight. The role of molecular configuration, as a factor influencing transport 
over the peritoneal membrane is not well established and studies on the role of molecular 
charge provide conflicting data [191-193]. Macromolecular transport from the peritoneal 
capillaries into the dialysate occurs by diffusion and convection. Some studies indicate that 
convection across large pores should be considered the main transport mechanism [91, 
194], whereas other studies favour restricted diffusion as the main mechanism [192,195, 
196]. 
Loss of proteins during CAPD could theoretically lead to deficiencies, although 
generally this does not cause problems in the clinical setting [180]. In a study by Schröder 
et al., serum IgG2 levels were not detectable in 11 of 12 children treated with CAPD 
[197]. It was presumed that this was due to loss with the dialysis fluid. 
Several studies have measured loss of complement factors during CAPD. In these 
studies loss of C3 and C4 was approximately as would be expected on the basis of 
molecular weight, but serum levels were normal [198-200]. Plasma levels of C3 were 
negatively correlated with duration of CAPD in one study [201], but this was not 
confirmed by others [198,200]. Dialysate levels of C3d and factor D are reported to be 
high, but this can be explained by high serum levels as a result of a reduced elimination 
of these low molecular weight proteins by the kidney [202,203]. 
Some studies have provided evidence for activation of complement in the peritoneal 
cavity during CAPD. Young et al. simultaneously measured a number of complement 
components in serum and dialysate and found relatively high levels of Bb, C3b and SC5b-
9 (the soluble form of the membrane attack pathway) in dialysate, suggesting activation 
of complement in the peritoneal cavity. Lewis et al. found a decreased C5a receptor 
availability on peripheral blood neutrophils and monocytes in CAPD patients, indicating 
continuous exposure of these cells to C5a [204]. Holmes et al. reported periodic elevations 
of C3bi in dialysate in 2 out of 8 CAPD patiens, not associated with peritonitis [205]. 
There arc no data available on the influence of CAPD on the complement system in 
children. 
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1.5 AIM OF THE STUDY 
The aim of this thesis is to investigate transport of macromolecules from the peritoneal 
cavity to the blood and from the blood to the dialysate in children treated with CAPD. 
The studies concerning fluid kinetics are presented in part II. In these studies 
transcapillary ultrafiltration and lymphatic absorption are measured in children treated with 
CAPD. Lymphatic absorption is estimated from the disappearance rate of an intraperito-
neally administered marker and transcapillary ultrafiltration is calculated from the dilution 
of the marker. In the three studies, presented in chapters 2, 3 and 4, three different volume 
markers were used, namely human albumin, autologous haemoglobin and dextran 70. 
Since macromolecules are absorbed from the peritoneal cavity by lymphatic absorption, 
intraperitoneal administration of drugs could be effective during CAPD. In part III the 
intraperitoneal administration of erythropoietin is explored. In chapter 5 a therapeutic study 
with erythropoietin administered intraperitoneally is presented. In chapter 6 the 
pharmacokinetics of erythropoietin, administered intraperitoneally in different concentra-
tions are compared to the pharmacokinetics of subcutaneous administration. 
In part IV the complement system is' studied. In chapter 7 serum levels of several 
complement factors and results of functional assays of the classical and alternative pathway 
in children treated with CAPD are compared to normal controls and to children with 
preterminal renal failure. The objective was, to see if a deficiency of complement can 
occur during CAPD as a result of loss of proteins with the dialysate. In chapter 8 serum 
and dialysate levels of complement factors were simultaneously measured in a group of 
children treated with CAPD. The purpose of this study was to establish if there is 
activation of complement in the peritoneal cavity, with local production or consumption 
of complement factors. 
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Summary 
Peritoneal fluid handling depends on a balance between transcapillary ultrafiltration and 
lymphatic absorption. Lymphatic absorption is reported to be greater in children than in 
adult continuous ambulatory peritoneal dialysis (CAPD) patients. The present study 
provides data on peritoneal fluid kinetics in a group of 17 young children (0.4 - 13 years 
of age). Net transcapillary ultrafiltration and lymphatic absorption were not dependent on 
age or duration of treatment. No differences were established from normal values for adult 
patients reported in the literature. 
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Introduction 
An important aim of treatment with CAPD is the regulation of the fluid balance in the 
patient. To obtain a sufficient ultrafiltration an osmotic agent, generally glucose, is added 
to the dialysis fluid. Not only is a fluid transport from the patient to the dialysate present 
(transcapillary ultrafiltration), but also a resorption of dialysis fluid, mainly through 
subdiaphragmatic lymphatics, has been established more recently [1]. This lymphatic 
absorption is reported to be higher in children than in adults [2]. The present study 
supplies data on peritoneal fluid handling in a group of 17 children. 
Patients and methods 
The study population consisted of 17 children (mean age 5.3 years; SD 4.0 years; range 
0.4-13.0). They were treated with CAPD for a mean period of 13.2 months (SD 18.2 
months; range 0.3-57). For the purpose of this study the group was subdivided into two 
groups according to the duration of treatment. The first group (n = 9; mean age 4.6 ± 3.5 
years; range 0.4-11.5) was in the first month of CAPD treatment. The second group (n = 
8; age 6.1 ± 4.5 years; range 2.3-13.0) was investigated at a later stage of treatment (mean 
duration of CAPD 27.6 months). 
Studies were performed after an overnight dwell with dialysis fluid (Dianeal 1.36%; 
Baxter, Deerfield, 111., USA). A volume of 40 ml/kg body-weight of Dianeal 3.86 % was 
instilled into the peritoneal cavity, with the addition of 15 g of human albumin (Centraal 
Laboratorium van de Bloedtransfusiedienst, Amsterdam, The Netherlands) per litre dialysis 
fluid. After a 6 h dwell period the dialysate was drained and the volume was carefully 
measured. Dialysate samples for the determination of albumin concentration were taken 
at 0 and 6 h. Calculation of net transcapillary ultrafiltration, lymphatic absorption, net 
calculated ultrafiltration, and measured ultrafiltration were performed using published 
methods [3].The following formulae were applied. 
(a) Net transcapillary ultrafiltration = x v 0 - C0 
_ T ,_ . u (V0 x C0) - (V6 χ C6) 
(b) Lymphatic absorption = — 
Cp 
(c) Calculated net ultrafiltration = (a) - (b) 
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(d) Measured net ultrafiltration = V6 - V0 
Where V0 and V6 = intraperitoneal volumes at times 0 and 6 h respectively, and where C0 
and C6 = dialysate albumin concentrations at times 0 and 6 h respectively. Cp = 
geometrical mean dialysate albumin concentration = V(C0 χ C6) 
Data were analyzed for the total group of patients and for the two subgroups of short 
duration of CAPD (< 1 month; η = 9) and longer duration of treatment (> 1 month; η = 
8). Differences between these subgroups were studied using Student's t-test. A Ρ value < 
0.05 was regarded as significant. To investigate the relation between age and kinetic 
parameters Kendall correlation coefficients were calculated. 
Net transcapillary UF 
ml/kg 
% init. vol. 
Lymphatic absorption 
ml/kg 
% init. vol 
Net calculated UF 
ml/kg 
% init. vol 
Measured UF 
ml/kg 
% init. vol 
Total group 
n = 17 
13.3 + 1.5 
33.7 ±3.3 
5.9 ± 1.0 
14.6 + 2.5 
7.5 + 1.0 
19.1 +2.3 
6.4 + 0.9 
16.5 ±2.2 
Subgroup < 1 month Subgroup > 1 
of CAPD 
n = 9 
12.1 ± 1.4 
30.3 ± 3.2 
5.7+ 1.2 
13.7 ±2.9 
6.5 ± 1.2 
16.6 ± 3.0 
5.6 ± 1.2 
14.5 ±3.1 
month of CAPD 
n = 8 
14.6 ±2.8 
37.5 ±6.0 
6.1 ± 1.9 
15.7 ±4.4 
8.6 ± 1.5 
22.0 ± 3.5 
7.3 ± 1.3 
18.7 ±3.2 
Table 1. Net transcapillary ultrafiltration (UF), Lymphatic absorption, net calculated 
ultrafiltration, and measured ultrafiltration in the total patient group, and in the subgroups in 
the first month and at later stages of CAPD treatment. 
Results 
Data on net transcapillary ultrafiltration, lymphatic absorption, net calculated ultrafiltration, 
and measured ultrafiltration are given in table 1. Figures are given for the total group and 
both subgroups, and are expressed as ml/kg body weight and as percentage of the initial 
intraperitoneal volume. There are no significant differences between the group just starting 
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with CAPD and the group with a mean duration of treatment of more than 2 years (P > 
0.25). Kendall correlation coefficients showed no significant age dependency with respect 
to net transcapillary ultrafiltration, lymphatic absorption, net calculated ultrafiltration, and 
measured ultrafiltration (P > 0.10). The relationship between net transcapillary 
ultrafiltration and lymphatic absorption, expressed as ml/kg body-weight, with the age of 
the patients are shown in figure 1. 
ml/kg 4 0 -
3 0 -
2 0 -
1 0 -
ml/kg 
π 1 1 1 1 1 1 
2 4 6 8 10 12 14 
16-
14-
12-
10-
8-
6-1 " 
4-
2-
age (years) 
π ι ι ι ι ι ι 
2 4 6 8 10 12 14 
age (years) 
Figure 1. Relationship between net transcapillary ultrafiltration (upper) and lymphatic 
absorption (lower) with age of the individual patients. 
Discussion 
Data on peritoneal fluid kinetics during childhood CAPD are scarce. In the only available 
study, Mactier et al. compared children with adult CAPD patients and reported a 
significantly greater net transcapillary ultrafiltration and lymphatic absorption in six 
children (mean age 9.3 years; range 2 - 13), treated for 19 months (range 10 - 47) with 
CAPD [2]. Our data are compared with theirs in table 2. We are not able to establish 
differences between our paediatric population and the adult patient group of Mactier et al. 
If the duration of the test is taken into account (6 h in the present study vs 4 h in 
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Net transcapi Mary UF 
ml/kg 
% init. vol. 
Lymphatic absorption 
ml/kg 
% init. vol 
Measured UF 
ml/kg 
% init. vol 
This series 
Children 
n = 17 
13.3 ± 1.5 
33.7 ± 3.3 
5.9 ± 1.0 
14.6+2.5 
6.4 ± 0.9 
16.5 ±2.2 
Mactier et al. 
Children 
n = 6 
15.4 + 2.1 
31 ± 4 
10.3 + 1.8 
20.4 ± 3.0 
4.1 ± 1.9 
9.2 + 3.8 
[2] 
Adults 
n = 10 
10.6 ± 1.2 ' 
34 +2.9 
4.4 ± 0,9 " 
13.9 + 2.7 
5.9 + 0.7 
19.1 ± 2 . 2 ' 
Table 2. Comparison of net transcapillary ultrafiltration (UF), lymphatic absorption, and 
measured ultrafiltration in the presented patient group with data obtained from literature [2]. 
Values are given as means + SEM. ' Ρ < 0.05; " Ρ < 0.01 for children vs adults. 
Mactier's) and linearity of lymphatic absorption with time is assumed, our observations 
show lymphatic absorption to be even less. Our different findings cannot be explained by 
a different age distribution (our patient group is younger) or by the effect of duration of 
С APD. Age dependency of the measured parameters was not observed. Since no data are 
available for neonates and infants below the age of 3 months, it is not possible to extend 
this statement to the neonatal period. A tendency towards more rapid transcapillary 
ultrafiltration and lymphatic absorption with duration of therapy may be present, although 
no significant difference was observed. 
Most studies on peritoneal fluid kinetics have been performed using human albumin as 
a volume marker. Several disadvantages, however, hamper the application of this 
substance. The most important disadvantage is the contribution of endogenous patient 
albumin to the dialysate. This will influence the results of the test: calculations of 
lymphatic absorption will give lower values, leading to underestimation. This is illustrated 
by the slightly reduced figures for measured ultrafiltration compared to net calculated 
ultrafiltration, both in our and in Mactier's study. In addition there are preliminary data 
reporting the augmentation of peritoneal solute transport by intraperitoneally administered 
human albumin [4]. Other volume markers have been applied: The use of radioactive 
iodinated serum albumin (RISA) or neutral dextrans certainly has advantages [5]. How­
ever, since RISA is radioactive this substance is not acceptable for routine use, especially 
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not in children. Autologous haemoglobin may be a suitable volume marker for future 
studies [6]. This volume marker is easy to obtain, non-toxic, and is not present in the 
dialysate under normal circumstances. 
Studies on peritoneal fluid handling are important for the institution of the individual 
schedule. This is illustrated by the large individual variation of the parameters presented 
in this study. Pharmacological reduction of the lymphatic absorption will possibly be 
important in the future for better fluid removal in individual patients. Even more important 
are these studies for the intraperitoneal administration of high-molecular-weight drugs. 
These drugs can only be taken up into the body by lymphatic absorption. In paediatric 
patients this will be especially important for growth hormone and erythropoietin. For 
growth hormone an acceptable resorption has been established [7]; for erythropoietin there 
are only data for adult patients [8-10]. Erythropoietin was resorbed only to a small amount 
according to two studies [8,9]. We observed serum erythropoietin concentrations 
comparable to those achieved after subcutaneous administration in nine children who 
received erythropoietin intraperitoneally (unpublished observations). Frenken et al. reported 
a good therapeutic result in five patients [10], although the dosage they needed was greater 
than most groups require using subcutaneous administration. The avoidance of needle 
pricks in small children is, however, a major advantage, advocating intraperitoneal 
administration of this drug. 
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Summary 
Previous measurements of peritoneal fluid handling in children treated by CAPD were 
performed with human albumin as a fluid marker. A major disadvantage of this substance 
is the fact that endogenous patient albumin enters the peritoneal cavity during the dwell 
period. For this reason peritoneal fluid kinetics were measured in 9 children treated by 
CAPD, using autologous haemoglobin as a fluid marker. Marker clearance (MC), which 
is presently the best available approximation of lymphatic absorption in the clinical setting, 
and transcapillary ultrafiltration (TCUF) were measured during a 4-hour dwell. MC was 
515 ± 156 ml/4 hr/1.73 m2 which is high as compared to literature data on adult CAPD 
patients. TCUF was 519 ± 92 ml/4 hr/1.73 m2, which is similar to data concerning adult 
patients. TCUF reached no maximum during the 4-hour dwell and the deviation of the 
TCUF curve from linear was markedly less than usually seen in adult patients. It is 
concluded that MC in children treated with CAPD is higher when compared to adults. 
Difficulties to achieve sufficient ultrafiltration in children could be caused by relatively 
small differences between MC and TCUF from the beginning until the end of the dwell. 
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Introduction 
The regulation of fluid balance is one of the main therapeutic goals in patients treated by 
continuous ambulatory peritoneal dialysis (CAPD). Net ultrafiltration in patients on CAPD 
is the result of both transcapillary ultrafiltration (TCUF) and fluid reabsorption. It has been 
reported that it is difficult to achieve sufficient ultrafiltration in children treated by CAPD 
[1]. This has been attributed to a more rapid absorption of glucose from the dialysis 
solution [1]. However, no significant difference was found in this respect between children 
younger and children older than 3 years [2]. 
Lymphatics play a significant role in the reabsorption of fluid from the peritoneal 
cavity. The lymphatic absorption rate in children has always been estimated from the 
disappearance rate of intraperitoneal macromolecules, since measurements of tracer 
appearance rates in blood are not feasible in the clinical setting. 
Flessner et al. recently performed studies in rats and found that only 20-25 % of the 
total protein loss from the peritoneal cavity could be attributed to lymphatic absorption [3]. 
The rest of the absorbed dose was found in the tissues surrounding the cavity. 
Struijk et al observed that the disappearance of dextran 70 did not change after satura-
tion of the tissues surrounding the peritoneal cavity with this marker [4]. This suggests that 
the disappearance rate of macro-molecules can be used as an indirect measurement of 
lymphatic absorption. 
Lindholm et al. propose a so-called 'peritoneal tissue compartment' and prefer to speak 
of peritoneal fluid reabsorption instead of lymphatic absorption [5]. This term does not 
acknowledge the fact that there may also be peritoneal fluid absorption not related to 
marker disappearance. 
Since the contribution of the lymphatics to the transfer of substances from the peritoneal 
cavity to the systemic circulation is not well established, we prefer to speak of marker 
clearance (MC) instead of lymphatic absorption. Marker clearance is the theoretical fluid 
loss from the peritoneal cavity, assuming that all marker loss is related to fluid loss. 
Marker clearance is presently the best available approximation of lymphatic absorption in 
the clinical setting. Higher MC in children has been reported and this could result in 
reduction of ultrafiltration [6]. 
In a previous study we measured TCUF and MC in a group of children and were not 
able to establish differences with values for adult patients reported in the literature [7]. Up 
to now peritoneal fluid handling in children has always been measured with human 
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albumin as a fluid marker. An important disadvantage of this substance is the fact that 
endogenous patient albumin enters the peritoneal cavity during the dwell period. In 
addition, augmentation of peritoneal solute transport by intraperitoneally administered 
albumin has been reported [8]. In adult patients autologous haemoglobin has been used as 
a fluid marker [9,10]. In the present study peritoneal fluid handling was analyzed in a 
group of children treated with CAPD using autologous haemoglobin as a volume marker. 
Patients and methods 
The study population consisted of 9 children, 3 girls and 6 boys, treated with CAPD. 
Median age of these children was 8.1 years (range 2.1-13.2). The median weight was 23.0 
kg (range 10.1-34.9). The children had been treated with CAPD for a median period of 
34 months (range 1-90 months). The causes of renal failure were renal dysplasia (2), 
urethral valves with dysplasia (1), polycystic kidney disease of the recessive form (1), 
haemolytic uraemic syndrome (1), nephronophtisis (1), cystinosis (1) and unknown (2). 
Informed consent was obtained from the parents of all patients after explanation of the 
purpose and methods of the study. The.protocol was approved by the committee of 
medical ethics of the University Hospital of Nijmegen. 
During a visit to our outpatient clinic 20 ml of blood was drawn under aseptic 
conditions. The blood was collected in a heparinized syringe and centrifuged for 30 
minutes at 1000g. Plasma and buffy coat were removed. Haemolysis was accomplished 
by adding sterile water. After 15 minutes, the sample was centrifuged for 30 minutes at 
3000g. The clear haemolysate was collected in a syringe. A sample was added to a blood 
culture medium to check sterility of the solution and 50 ml was transferred into a sterile 
bag and stored at - 20°C. 
Studies were only done if sterility of the haemolysate was proven. Each experiment was 
performed during a 4-hour dwell. Bags with the amount of dialysis fluid normally used 
by the child were applied containing 1.36 % glucose (Dianeal 1.36 %, Baxter Inc., 
Deerfield, IL, USA). During the dwell the patient remained in the supine position. Before 
the instillation of the test bag containing autologous haemoglobin, the peritoneal cavity 
was rinsed twice with the normal volume of dialysis fluid. Two three-way cocks were 
inserted into the CAPD-system. The proximal cock was used for sampling. A 50 ml 
syringe was connected to the distal cock. Every sampling of dialysis fluid was preceded 
by temporarily drawing 50 ml of dialysate into the 50 ml syringe. Inflow and outflow 
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volumes were measured by subtracting the weight of an emptied bag from the weight of 
the full bag and dividing this by the specific gravity of the used dialysis fluid. 
The haemolysate was defrosted and added to the dialysis fluid. After mixing a sample 
was taken for the determination of the initial concentration of haemoglobin, glucose, 
sodium and chloride and for the determination of the osmolarity of the solution. During 
infusion of the test bag the patient rolled from side to side to promote intraperitoneal 
mixing of the dialysate. When the inflow was completed, 5 ml of dialysis fluid was 
sampled after 5, 30, 60, 120, 180 and 240 minutes. The concentrations of haemoglobin, 
glucose, sodium, chloride and urea and the osmolarity were determined in these samples. 
The peritoneal cavity was drained immediately after the last sample. After this, the 
peritoneal cavity was rinsed twice. The concentrations of haemoglobin in the outflow bags 
were measured in order to be able to calculate postexchange residual volume (RV). 
Haemoglobin concentrations were measured with a three-wavelength polychromatic 
analysis [11]. The coefficient of variation of the haemoglobin determinations was 0.5 % 
in the concentration range relevant for this investigation. All values were expressed as 
mean ± SD. Correlations were calculated by the method of least squares. 
Calculations 
For the calculations the principles of Nolph et al. were applied, adapted by Krediet et al. 
[12,13]. Marker clearance (MC) was calculated as the difference between the amount of 
haemoglobin instilled and the total amount recovered, divided by the product of dwell time 
and the mean haemoglobin concentration. It was assumed that MC is a linear process. The 
following formula was used, where V, is the volume, C, is the haemoglobin concentration 
of the test bag, V240 is the drained volume of the test bag, RV^, is the calculated 
postexchange residual volume, C, is the haemoglobin concentration at time t and S is the 
sample volume: 
MC ШМШ - ^ ^ > - ^ o * ( W * W - s * (C5 +••••+ c240) 
2 4 0 X / ( C 5 X C2i0) 
The intraperitoneal volume (IPV,) was calculated as the amount of haemoglobin in the 
peritoneal cavity divided by the haemoglobin concentration. The calculations of IPV0, 
IPV30 and IPVjd are shown below. IPV120, IPV180 and IPV240 were calculated in a similar 
way. 
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I P V Ш) - (c>xV¿ ' M C x S x^c5xc2i0) 5
 c5 
IPVi0 (ml) = °" x HPV* - 5 ' - MC χ 25 χ J(C5 χ СМУ 
'-зо 
IPV (ml) = Сз° x ( J W 3 0 - 5 ) - Я С х 3 0 х ^ / ( С 5 х C 2 7J 
C 6 L 
The theoretical intraperitoneal volume (TIPV,), that is, the intraperitoneal volume in the 
absence of MC and sampling, was determined by adding cumulative sample volume (SJ 
and MC: 
TIPVt (ml) = IPVt + St + MC X t 
Transcapillary ultrafiltration was calculated by subtracting the initial theoretical 
intraperitoneal volume (TIPVS) from the theoretical intraperitoneal volume: 
net TCUFC (ml) = TIPV,. - TIPV5 
Net ultrafiltration (UF) can be calculated or measured: 
net calculated UF (ml) = TCUFC - MC χ t 
net measured UF (ml) = V240 - V1 + St 
The preexchange residual volume (RV^) and postexchange residual volume (RV^J 
were calculated with the formulas below, in which V
r
 is the inflow volume and C
r
 the 
haemoglobin concentration after drainage of the first rinsing bag. 
RVple (ml) = V, χ Ь - V, 
RV^ (ml) = VT χ C j 
l L
-240 W 
Results 
Four out of 9 children indicated brief abdominal pain during instillation of the test bag. 
No patient developed peritonitis shortly after the study. 
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no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
age 
8.1 
13.2 
7.5 
8.7 
6.0 
7.5 
2.1 
12.4 
10.9 
sex 
F 
M 
M 
F 
M 
M 
M 
M 
F 
weight 
23.4 
34.9 
23.0 
18.3 
20.4 
18.9 
10.1 
34.3 
26.2 
height 
119.5 
142.5 
121.5 
116.5 
112.5 
114.0 
78.5 
139.0 
141.3 
inflow 
volume 
793 
1039 
773 
764 
601 
601 
443 
1044 
1039 
drain 
vol­
ume 
778 
1039 
823 
700 
601 
586 
389 
1177 
1079 
MC 
374 
480 
204 
209 
208 
318 
151 
188 
216 
TCUF 
329 
428 
313 
232 
190 
206 
133 
324 
235 
pre 
RV 
146 
196 
178 
0 
74 
174 
20 
91 
ПО 
post 
RV 
87 
115 
209 
44 
27 
48 
26 
64 
61 
Table 1. Age, sex, weight, height, dialysate inflow volume and drain volum, marker clearance 
and transcapillary ultrafiltration, and preexchange and postexchange residual volume (ml) in 
the patients. 
MC 
TCUF 
cale UF 
meas UF 
RVpre 
RV, 
RVpre - RVpost 
ml/kg 
11.7 ± 3.9 
11.6 ± 2.0 
-0.1 + 3.3 
1.2 ± 2.3 
4.6 ± 2.9 
3.2 ± 2.3 
1.3 ± 2.7 
% init IPV 
29.7 ± 9.3 
29.5 ± 4.5 
-0.2 ± 8.4 
3.3 ± 6.1 
11.7 ± 7.1 
8.1 ± 5.5 
3.6 ± 6.6 
ml/1.73 m2 
521 + 166 
519 ± 92 
-2 ± 148 
59 ± 106 
209 ± 131 
146 ± 106 
63 + 116 
Krediet et al. 
(9) (ml) 
382 ± 146 
468 ±217 
78 ± 182 
-23 ±214 
259+ 20 
304 ± 148 
-61 ± 178 
Table 2. Markerclearance, transcapillary ultrafiltration, calculated and measured ultrafiltration, 
preexchange and postexchange residual volume and preexchange minus postexchange residual 
volume during a 4-hour dwell period. Values are expressed in relation to body weight, initial 
intraperitoneal volume and body surface area (N = 9). The results are compared to data from 
the study of Krediet et al. (9). 
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The dialysate haemoglobin concentration before instillation was 139 ± 58 mg/dl. The 
instilled volume was 35.5 ± 5.2 ml/kg. The glucose concentration of the test bag was 61 
± 4 mmol/1, the sodium concentration 123 ± 4 mmol/1 and the chloride concentration 91 
± 4 mmol/1. The osmolality of the test bag was 306 ± 8 mOsm/1. Concentrations in the 
drained bag were: glucose 23 ± 6 mmol/1, sodium 1 3 3 + 4 mmol/1, chloride 104 ± 6 
mmol/1 and urea 22 ± 4 mmol/1. The osmolarity of the drained bag was 307 ± 9 mOsm/1, 
similar to the osmolarity of the test bag. 
Z^. VOLUME 
(ml/1.73 m2) 
700 -ι 
TIME (minutes) 
Figure 1. The time course of transcapillary ultrafiltration during the 4 hour dwell (closed 
circles). Marker clearance is indicated as a dotted line. Values are given as means ± 1 standard 
deviation (N = 9). To facilitate comparison mean transcapillary ultrafiltration in adult patients 
studied by Krediet et al. is also shown (open circles) (9). It was assumed that mean body 
surface area was 1.73 m2 in these patients. 
Individual data on MC, TCUF and RV are given in Table 1. Overall results are given 
in Table 2. In order to facilitate comparison to adult data, results in this table are 
expressed in relation to body surface area (1.73 m2), body weight and percentage of initial 
intraperitoneal volume (= dwell volume + preexchange residual volume). 
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Cumulative MC during the 4-hour dwell was 521 ± 166 ml/1.73 m2, while cumulative 
TCUF was 519 + 92 ml/1.73 m2. The mean marker clearance of 2.17 ml/min/1.73 m2 was 
high in comparison to data of Krediet et al. obtained in adult CAPD patients, assuming 
that mean body surface area was 1.73 m2 in that study [9]. Although cumulative TCUF 
was similar to adult patients, the deviation of the TCUF curve from linear was minimal. 
The curves for children and adults are compared in Figure 1. 
Mean preexchange RV was higher than postexchange RV but this difference was not 
statistically significant (paired T-test). A poor correlation was found between preexchange 
and postexchange RV: r=0.65, PO.05. 
Discussion 
Only limited data are available on peritoneal fluid handling in children on CAPD. Mactier 
et al. measured MC and TCUF in adults and children during a 4-hour dwell and both were 
found to be significantly higher in children in relation to body weight [6]. In a similar 
study during a 6-hour dwell our group reported values for MC and TCUF in children that 
were similar to values obtained in adult patients [7]. In both studies human albumin was 
used as a fluid marker and dialysis fluid was used with a glucose concentration of 2.27 
% [6] and 3.86 % [7]. An important disadvantage of the use of albumin as a fluid marker 
is the fact that endogenous patient albumin enters the peritoneal cavity during the dwell. 
In addition, augmentation of peritoneal solute transport by intraperitoneally administered 
albumin has been reported [8]. 
Other fluid markers have been applied [13,14]. In the present study autologous 
haemoglobin was used as a volume marker. This substance has been successfully applied 
by Krediet et al. and Brouard et al. in adult CAPD patients [9,10]. Advantages of this 
substance are that it is not usually present in the peritoneal cavity and that there is no risk 
of sensitization. 
There are also a number of disadvantages. The production of autologous haemoglobin 
is very time-consuming and carries the risk of contamination. The addition of a relatively 
high volume of haemolysate, with low osmolarity, changes the composition of the dialysis 
fluid. This may influence fluid kinetics. Furthermore, lymphatic absorption may be altered 
by intraperitoneal administration of haemoglobin, since haemoglobin suppresses lymphatic 
pumping in vitro [15]. Finally, impurities of the haemoglobin solution, such as stromal 
components, can have certain toxic effects [16]. The fact that some patients suffer from 
brief abdominal pain during instillation of the haemoglobin solution suggests that one or 
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more toxic factors are indeed acting upon the peritoneal membrane. However, there was 
no difference in peritoneal fluid kinetics between children with and children without 
abdominal pain. 
In order to facilitate comparison with data of Krediet et al. and data of Mactier et al., 
we decided to study a 4-hour dwell [6,9]. We used dialysate containing 1.36 % glucose 
to simplify comparison to the data of Krediet et al. [9]. Actually, our study was performed 
almost exactly identical to that study. The results of our study are compared to data of 
Mactier et al. and Schröder et al. in Table 3. 
this series 
N=9 
Marker clearance 
ml/kg 
% init IPV 
ml/1.73 m2 
Transcapillary 
ml/kg 
% init IPV 
ml/1.73 m2 
11.7 ± 3.9 
29.7 ± 9.3 
521 ± 166 
ultrafiltration 
11.6 ± 2.0 
29.5 ± 4.5 
519 ±92 
Schröder et al. 
N=17 
5.9 ± 4.3 
14.6 ± 10.3 
249 ± 173 
13.3+ 6.2 
33.7 ± 13.6 
513 ±254 
(7) Mactier et al. 
children 
N=6 
10.3 ± 4.4 
20.4 ± 7.3 
469 ± 203 
15.4 ± 5.1 
31.0 ± 9.8 
702 ± 258 
(6) 
adults 
N=10 
4.4 ± 2.8 
13.9 ± 8.5 
311 ±197 
10.6 ± 3.8 
34.0 ± 9.2 
744 ±230 
Table 3. Comparison of marker clearance and transcapillary ultrafiltration in the studied 
patient group with data obtained from literature. Total volumes per dwell are expressed in rela-
tion to body weight, initial intraperitoneal volume and body surface area (N = 9). 
The peritoneal surface area of a newborn infant is about twice that of an adult in 
relation to body weight [17]. The ratio of body surface area to weight is also larger in 
children [18]. If fluid kinetics in children and adults are compared, correction for body 
surface area is probably the most appropriate way. In order to allow optimal comparison 
to literature data, all results were expressed not only in relation to body surface area but 
also in relation to body weight and initial intraperitoneal volume. 
Marker clearance was high in our study group, corrected for body surface area 521 ± 
166 ml/4 hr/1.73 m2. Krediet et al. reported a net MC of 382 ± 146 ml/4 hr in a group of 
16 adult patients [9]. In another study a much slower MC of only 8 ml/hr was established 
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[10]. In the latter study the preexchange residual volume was assumed to be equal to the 
postexchange residual volume and used to calculate recovery of haemoglobin. This 
assumption may not be valid, since we found only a poor correlation between preexchange 
and postexchange residual volume. Additionally, the haemoglobin concentration of the 
instillation bag was less than 40 mg/dl. In this concentration range, minor errors in the 
measurements of haemoglobin concentrations will result in major errors in the calculation 
of MC. As shown in Table 3, our data on MC resemble those found by Mactier et al. in 
children, although MC was somewhat lower in his study group [6]. This could be the 
result of contribution of endogenous patient albumin to the dialysate resulting in 
underestimation of MC. 
In the study by Schröder et al. a much lower MC was reported, especially if the fact 
that a 6-hour dwell was studied is taken into account (Table 3.). In this study albumin was 
used from the central laboratory of the Netherlands Red Cross Blood Transfusion Service. 
Struijk et al. reported that the peritoneal transport of small solutes and immunoglobulin 
G significantly increased in response to intraperitoneal administration of this substance [8]. 
The mass transfer area coefficient for IgG for instance, increased from 0.05 to 0.11 
ml/min. This was attributed to contamination of the product with prekallikrein activator. 
It can be calculated that an increase in the dialysate albumin concentration with approxi-
mately 1.5 g/1, due to augmentation of peritoneal transport, could explain the erroneously 
low MC in the study of Schröder et al. 
Lymphatic absorption probably mainly occurs at the peritoneal surface of the diaphragm 
via stornata [19,20]. In relation to body surface area, the surface area of the diaphragm is 
similar in adults and children [17]. Diaphragmatic movements are thought to be important 
for lymphatic absorption [21]. The higher ventilatory rate in children could explain the 
high values we found for MC. It must be noted however, that there was no relationship 
between age and MC in our study group. A difference in the number of functioning 
stornata between adults and children cannot be excluded. 
We assumed that MC is a linear process. This is supported by the observation that fluid 
and protein absorption from the peritoneal cavity is relatively constant [12,22]. Variability 
of MC during a dwell period was however observed in an animal study by Breborowicz 
et al. [23]. 
Transcapillary ultrafiltration was low compared to the data of Mactier et al. and 
Schröder et al. (Table 3.) [6,7]. It must be realized, however, that we used a slightly 
different formula to estimate TCUF. This mode of calculation prevents overestimation of 
TCUF, by taking into account loss of marker by sampling and MC. If the equations used 
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by Schröder et al. and Mactier et al. were employed to calculate TCUF in our study group, 
TCUF would have been 13.8 + 2.1 ml/kg, which is similar to the results of both studies. 
Since TCUF is probably underestimated in the studies of Schröder et al. and Mactier 
et al. as a result of contribution of endogenous patient albumin to the dialysate, TCUF 
appeared to be low in our study group. This is not surprising, since TCUF would be 
expected to be less in the present study, because the glucose concentration of the dialysate 
employed was lower. 
In comparison to the data of Krediet, TCUF related to body surface area was similar 
in our study group, approximately 500 ml in 4 hours [9]. The shape of the TCUF curve, 
however, appeared somewhat different from the curve obtained in adult patients [9]. 
In some of our patients the relation between time and TCUF was linear; the others 
showed only minimal deviation from linear. The domination of TCUF over MC in the 
beginning of the dwell was minimal. It must be realized that the curves might have been 
different if plain dialysate containing 1.36 % glucose was used, since the addition of 
haemolysate altered the composition of the dialysate. However, the shape of the curve was 
similar in all patients and appeared unrelated to the amount of change in dialysate 
composition. The addition of a marker to the dialysate will always alter its composition. 
The magnitude of this phenomenon is dependent on the quantity that has to be added to 
be able to perform correct measurements. A major disadvantage of autologous haemoglo-
bin as a fluid marker is the fact that rather large quantities have to be added in order to 
achieve an adequate concentration. 
Postexchange RV in adults was 304 ± 148 ml/1.73 m2 in the study of Krediet et al., 
whereas it was 146 ± 106 ml/1.73 m2 in our study group [9]. Calculations were performed 
in an identical way. Preexchange RV was usually somewhat higher than postexchange RV 
in our study group. Preexchange RV was calculated using the haemoglobin concentration 
after 5 minutes. Maybe preexchange RV was overestimated because some TCUF had 
already taken place before sampling. Another possibility is binding of tracer to the lining 
of the peritoneal cavity. The difference between preexchange and postexchange RV 
accounts for the difference between calculated and measured ultrafiltration. 
It is concluded that measurements of peritoneal fluid kinetics in children with 
autologous haemoglobin as a volume marker are feasible, although this substance has some 
major disadvantages. Marker clearance, which was measured as an approximation of 
lymphatic absorption, in children treated with CAPD was found to be higher when 
compared to adults. High MC in children may explain the good results reported with 
intraperitoneal administration of erythropoietin [24]. During a 4-hour dwell with dialysate 
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containing a low glucose concentration, TCUF rate was almost linear. Difficulties to 
achieve sufficient ultrafiltration in children could be caused by relatively small differences 
between MC and TCUF from the beginning until the end of the dwell. Further studies are 
necessary to establish whether the differences between TCUF and MC become more 
pronounced using dialysate with a higher osmolarity. 
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Summary 
Fluid kinetics were studied in children treated with continuous ambulatory peritoneal 
dialysis (CAPD) aged between 2 and 15 years. Dextran 70 was used as a volume marker. 
A 4-hour dwell was studied with a dwell volume of 40 mL/kg. Transcapillary 
ultrafiltration (TCUF) was measured as well as marker clearance (MC), which is the best 
available approximation of lymphatic absorption in the clinical setting. In 11 children in 
whom dialysate was used containing 1.36 % glucose TCUF was 250 ± 79 mL/4 hour/ 
1.73 m2 and MC 236 ± 101 mL/4 hour/1.73 m2. In 13 children dialysed with 3.86 % 
glucose, TCUF was 829 ± 226 mL/4 hour/1.73 m2 and MC 307 ± 176 mL/4 hour/1.73 m2. 
These values are similar to those found in adult patients. There was a positive correlation 
between age and TCUF in the group receiving dialysate containing 3.86 % glucose 
(r=0.69, P=0.009). There was no correlation between age and MC. It is concluded that 
fluid kinetics in children and adults on CAPD are similar when corrected for body surface 
area. In young children TCUF is lower, probably because dwell volume is low in relation 
to peritoneal surface area in these children. 
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Introduction 
It has been reported that it is difficult to remove fluid from the body in young children 
treated by continuous ambulatory peritoneal dialysis (CAPD) [1]. A rapid reabsorption of 
glucose from the dialysis solution and a high lymphatic absorption rate have been 
suggested as possible causes [1,2]. 
The lymphatic absorption rate in children has always been estimated from the disappear­
ance rate of intraperitoneally administered macromolecules, since measurements of 
appearance rates in blood are not easily accomplished in the clinical setting. The 
contribution of the lymphatics to the transfer of substances from the peritoneal cavity to 
the systemic circulation is not well established. For this reason we adopted the term 
marker clearance (MC) instead of lymphatic absorption [3]. Different markers have been 
used by various investigators. 
Dextran 70 has proven to be an excellent marker for the study of fluid kinetics in adult 
patients [4]. The substance is not normally present in the human body, it can be safely 
administered intraperitoneally and concentrations in dialysate can be determined accurately. 
In the present study this marker was used to study peritoneal fluid handling in children 
treated with CAPD. 
Patients and methods 
Two groups of children were studied. In group A dialysate with a glucose concentration 
of 1.36 % was used and in group В with a concentration of 3.86 % (Dianeal, Baxter Inc., 
Deerfield, IL, USA). 
Group A consisted of 11 children, 3 girls and 8 boys, with a median age of 7.2 years 
(range 2.5-12.5). They had been on CAPD for a median period of 31.2 months (range 2-
93). Causes of renal failure were: posterior urethral valves (4), renal hypoplasia/dysplasia 
(4), polycystic kidney disease (adult type), congenital nephrotic syndrome and hypo-
reninemic hypoaldosteronism. There were 13 children in group B, 3 girls and 10 boys. 
Their median age was 7.0 years (range 3.1-15.4) and they had been treated by CAPD for 
a median period of 28 months (range 1-101). Causes of endstage renal disease were: 
posterior urethral valves (4), renal hypoplasia/dysplasia (4), polycystic kidney disease 
(adult type), congenital nephrotic syndrome (2), haemolytic uraemic syndrome and 
glomerulonephritis. Nine children were in group A as well as in group B. Informed 
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consent was obtained from the parents of all patients. The protocol was approved by the 
committee of medical ethics of the University Hospital of Nijmegen. 
Before the instillation of the test bag the peritoneal cavity was rinsed twice with the 
normal volume of dialysis fluid and 45 mg/kg dextran 1 (Promiten® NBPI, Emmercom-
pascuum, The Netherlands) was administered intravenously to prevent dextran induced 
anaphylactoid reactions [5]. Inflow and outflow volumes were measured by subtracting the 
weight of an emptied bag from the weight of the full bag and dividing this by the specific 
gravity of the used dialysis fluid. During the dwell period the patient remained in the 
supine position. 
Dextran 70 (Macrodex® NBPI, Emmercompascuum, The Netherlands) was added to 
a bag to a final concentration of approximately 4 g/1. Subsequently fluid was removed 
from the bag so that it would contain 40 mL/kg. After mixing a sample was taken for the 
determination of the initial concentration of dextran, glucose, sodium and chloride and for 
the determination of the osmolarity of the solution. During infusion of the test bag the 
patient rolled from side to side to promote intraperitoneal mixing of the dialysate. When 
the inflow was completed, 6 mL of dialysis fluid was sampled after 5, 30, 60,120 and 180 
minutes. The concentration of dextran was determined in these samples. After 240 minutes 
the peritoneal cavity was drained. In the outflow bag the concentration of dextran, glucose, 
sodium and chloride and the osmolarity of the solution were determined. Subsequently, 
40 mL/kg dialysate was instilled and drained immediately. The dextran concentration was 
measured in the effluent for calculation of post-exchange residual volume. 
Dextran concentrations were measured by means of high-performance liquid 
chromatography [6]. The coefficient of variation was 1.0 % in the concentration range 
relevant for this investigation. Calculations of MC, transcapillary ultrafiltration (TCUF), 
net ultrafiltration and pre-exchange and post-exchange residual volume were performed 
as published previously [3]. A full description of the calculation is given in the appendix. 
All data are expressed as mean ± SD. Statistical comparisons between the groups were 
performed using the paired t-test. Correlations were calculated by the method of least 
squares (Pearson). Any ρ values less than 0.05 were considered significant. 
Results 
Concentrations of dextran, glucose, sodium and chloride and the osmolarities of inflow and 
outflow bags in group A and В are given in Table 1. 
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dextran 
glucose 
sodium 
chloride 
osmolarity 
Group A 
inflow 
3634 ± 86 
69 ± 7 
134 ± 2 
104 ± 1 
334 ± 6 
outflow 
2889 + 214 
19 + 5 
136 ± 4 
108 ± 5 
313 ± 12 
Group В 
inflow 
3959 ± 237 
196 ± 13 
134 ± 3 
106 ± 3 
472 ± 11 
outflow 
2373 ± 209 
40 ± 12 
130 + 6 
105 ± 6 
321 ± 14 
Table 1. Concentrations of dextran (mg/l), glucose (mmol/1), sodium (mmol/1) and chloride 
(mmol/1) and the osmolarity (mOsmol/1) of the inflow and outflow bags of group A (1.36 % 
glucose dialysate) and В (3.86 % glucose dialysate). 
В 
1000 /\ Volume 
1 2 3 4 
time (hours) 
Figure 1. The time course of transcapillary ultrafiltration (A) and marker clearance (•) in 
group A (1.36 % glucose dialysate) and group В (3.86 % glucose dialysate) during the 4 hour 
dwell. Values are given as means ± 1 SD. 
The changes in TCUF and MC during the dwell are shown in Figure 1. In Table 2 the 
results are expressed in relation to body surface area (1.73 m2), body weight and 
percentage of initial intraperitoneal volume (= dwell volume + pre-exchange residual 
volume). For comparison, data corrected for body surface area, from a study by Imholz 
et al. in 10 adult CAPD patients is also given [unpublished information from 4]. 
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mL/kg % init IPV mL/1.73 m2 
Group A 
MC 
TCUF 
cale UF 
meas UF 
Rvpre 
Rv^, 
RVpre - RVpost 
5.6 ± 2.5 
5.8 ± 1.6 
0.2 ± 3.0 
0.8 ± 3.6 
4.4 ± 1.9 
3.9 ± 2.8 
0.5 ± 3.0 
12.4 ±4.9 
13.1 ±3.6 
0.7 ± 6.6 
1.8 ±7.9 
9.8 ± 3.7 
8.7 ± 6.3 
1.0 ±6.8 
236 ± 101 
250 ± 79 
14 ± 130 
36 ± 161 
190 ± 86 
168 ± 129 
22 ± 137 
Group В 
MC 
TCUF 
cale UF 
meas UF 
RVpre 
RV^, 
Rvp r e - RVP0S1 
6.7 ± 3.6 
18.0 + 3.1 
11.4 ±5.0 
13.5 ±5.1 
7.2 ± 4.2 
5.1 ± 3.0 
2.2 ± 3.7 
14.2 ± 7.3 
38.7 ± 7.3 
24.5 ± 11.4 
28.8 ± 10.3 
14.8 ± 7.0 
10.6 ± 5.9 
4.2 ± 7.0 
307 ± 176 
829 ± 226 
522 ± 244 
633 ±312 
342 ± 250 
233 ± 147 
110 ± 193 
Imholz et al. 
mL/1.73 m2 
340 ± 105 
292 ±148 
-55 ± 61 
317 ± 93 
819 ± 173 
500 ± 40 
Table 2. Marker clearance, transcapillary ultrafiltration, calculated and measured net 
ultrafiltration, pre- and post-exchange residual volume and pre- minus post-exchange residual 
volume during the 4-hour dwell period in group A (1.36 % glucose dialysate) and В (3.86 % 
glucose dialysate). Values (means + SD) are expressed in relation to body weight, initial 
intraperitoneal volume and body surface area. The results are compared to data from a study 
of Imholz et al. corrected for body surface area [unpublished information from 4]. 
Cumulative MC during the 4-hour dwell was 236 ± 101 mL/1.73 m2 in group A and 
307 ± 176 mL/1.73 m2 in group B. Cumulative TCUF was 250 ± 79 mL/1.73 m2 in group 
A and 829 ± 226 mL/1.73 m2 in group B. These data and also the aspect of the TCUF 
curve in the studied children are similar to those published by Imholz et al., concerning 
adult CAPD patients [4]. In the 9 patients who were in group A and group B, the 
difference in TCUF was statistically significant (P < 0.001), whereas the difference in MC 
was not. 
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The relationship between the age of the patient and MC and TCUF is shown in Figure 
2. The correlation between age and TCUF was significant in group В (r=0.69, P=0.009), 
while this correlation was not significant in group A (r=0.53, P=0.09). There was no 
correlation between age and MC. 
500 
Δ Volume 
(ml/1.73 m2) 
-500-
1000-
500-
5 10 
age (years) 
Figure 2. The relation between the age of the patient and nettranscapillary ultrafiltration ( A ) 
and net marker clearance (•) during the 4 hour dwell in group A (1.36 % glucose dialysate) 
and group В (3.86 % glucose dialysate). The linear regression line is given for the relation 
between age and transcapillary ultrafiltration. 
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Discussion 
The control of fluid balance is an important aspect of the management of patients treated 
by CAPD. In young children with chronic renal failure, CAPD is the preferred mode of 
therapy. In these children difficulties to achieve sufficient net ultrafiltration have been 
reported [1]. Net ultrafiltration is the difference between inflow of fluid into the abdominal 
cavity by transcapillary ultrafiltration (TCUF) and removal of fluid by lymphatic 
absorption (LA). A low TCUF as well as a high LA could result in a low net 
ultrafiltration. Balfe et al. established a low glucose concentration in the dialysate effluent 
of children aged under 6 years. They suggested that a more rapid absorption of glucose 
from the dialysis solution in these children may impede TCUF [1]. 
In children LA has always been estimated from the disappearance rate of intraperito-
neally administered macromolecules. The alternative, calculation of LA from tracer appear-
ance rates in blood is not easily accomplished in the clinical setting. Flessner et al. 
performed studies in rats and found that the appearance rate of labelled immunoglobulin 
G in blood was approximately 20 % of the disappearance rate from the peritoneal cavity 
[7]. Large amounts of the radioactive tracer were found in the tissues surrounding the 
abdominal cavity. Apparently fluid and solutes are forced into a peritoneal tissue 
compartment, from which they are removed by intratissue lymphatics [8]. Subdiaphrag-
matic lymphatics and intratissue lymphatics together account for total lymphatic uptake 
from the peritoneal cavity. The tracer disappearance rate can be used to estimate total 
lymph flow [9]. Since the contribution of the lymphatics to the transfer of substances from 
the peritoneal cavity is not well established, we prefer to use the term marker clearance 
(MC) when the tracer disappearance rate is used to estimate LA [3]. Marker clearance is 
the best available approximation of total LA in the clinical setting. 
Data on peritoneal fluid handling in children treated with CAPD are scarce. Mactier et 
al. measured MC and TCUF in 6 children and 10 adults and both were found to be higher 
in children in relation to body weight [2]. This was not confirmed in a study by Schröder 
et al. of 17 children [10]. In these children MC and TCUF was similar to adult patients. 
In both studies human albumin was used as a fluid marker. An important disadvantage of 
this substance is the fact that endogenous patient albumin enters the peritoneal cavity 
during the dwell. Also, augmentation of peritoneal solute transport by certain brands of 
intraperitoneally administered albumin has been reported [11]. 
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Autologous haemoglobin has also been used as a marker for the study of peritoneal 
fluid handling [3,12]. This marker also has a number of disadvantages. The preparation 
of the haemoglobin solution is very time-consuming and carries the risk of contamination. 
In order to achieve an acceptable haemoglobin concentration large amounts of haemolysate 
have to be added to the dialysis fluid, changing its composition and altering its osmolarity. 
Furthermore, intraperitoneal administration of autologous haemoglobin may directly 
influence MC, since it has been shown to suppress lymphatic pumping in vitro [13]. 
Finally, intraperitoneal administration of autologous haemoglobin can cause abdominal 
pain [3]. 
Dextran 70 has also been used successfully as a marker for the measurement of fluid 
kinetics in adults on С APD [4,14]. In previous studies in adults the concentration of 
dextran 70 in the test bag was 10 [14] and 1 g/1 [4]. In the present study the concentration 
was approximately 4 g/1. In this concentration range the estimation of the dialysate dextran 
level is accurate and the change in composition of the dialysis fluid minimal. The 
osmolarity of dialysate containing 1.36 % glucose is 347 mOsmoH. In the present study 
the mean osmolarity of the test bag was 334 mOsm/1 in patients in whom dialysate was 
used with 1.36 % glucose, while it was only 306 mOsm/1 in our former study with 
autologous haemoglobin as a marker [3]. 
The results of the measurements of MC and TCUF in the present study are similar to 
those in adults, when corrected for body surface area. Peritoneal surface area is 
proportional to body surface area [15]. For this reason we believe that correction for body 
surface area is probably the most appropriate way to compare fluid kinetics between 
children and adults. The present results are distinctly different from those of our previous 
study, in which autologous haemoglobin was used as a marker. These differences can 
probably be ascribed to effects of haemolysate on peritoneal permeability, MC and 
dialysate osmolarity. 
If MC and TCUF in children and adults are similar, the problem of (net) ultrafiltration 
failure in young children on CAPD remains unsolved. Very young children, below the age 
of 2 years, were not included in the present study. Nevertheless a positive correlation was 
established between age and TCUF and not between age and MC. A relatively low TCUF 
in young children will impede net ultrafiltration. This may be caused by the fact that body 
weight, and not body surface area, is used to calculate the dwell volume. It is common 
practice, and this was also done in the present study, to apply a dwell volume of approxi­
mately 40 mL/kg. As a consequence of this, dwell volume in relation to body surface area 
is relatively small in young children. While dwell volume is 2000 mL/1.73 m2 in an adult, 
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it is only approximately 1500 mL/1.73 m2 in a one year old child and only about 1000 
mL/1.73 m2 in a neonate. Dwell volume in young children is also low in relation to 
peritoneal surface area, since peritoneal surface area is proportional to body surface area 
[15]. Because of this equilibration between dialysate and serum occurs sooner and TCUF 
will be less. 
It emerges from the above, that it would be more logical to relate dwell volume to body 
surface area. Since the volume of the peritoneal cavity is related to body weight, one 
would assume that a dwell volume of 2000 mL/1.73 m2, which would be similar to adults, 
would not be tolerated in young children. However, in a study by Fischbach et al. the 
intraperitoneal pressure was measured using a dwell volume of 1000 mL/1.73 m2 and was 
found to be relatively low in infants below the age of one year [16]. The use of dwell 
volumes related to body surface area was recently proposed by Kohaut et al. [17]. They 
advised to use dwell volumes of 1200 mL/m2 when urea and glucose equilibration studies 
are being done to compare individuals of different ages and sizes. 
It is concluded that dextran 70 is a suitable marker for the study of fluid kinetics in 
children on CAPD. In children above the age of 2 years fluid kinetics, corrected for body 
surface area, are similar to those found in adult CAPD patients. There is a positive 
relationship between age and TCUF. Net ultrafiltration failure in young children may be 
the result of a low TCUF. This could be caused by the fact that the dwell volume, which 
is calculated from body weight, is relatively small in relation to peritoneal surface area. 
In the future, peritoneal fluid kinetics in children on CAPD should be studied with dwell 
volumes calculated on the basis of body surface area. 
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Appendix 
Marker clearance (MC) was defined as the difference between the amount of dextran instilled and 
the total amount recovered, divided by the product of dwell time and the mean dextran concentration. 
It was assumed that MC is a linear process. The following formula was used, where V, is the 
volume, C, is the dextran concentration of the test bag, V240 is the drained volume of the test bag, 
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RIPOSI ' s the calculated post-exchange residual volume, C, is the dextran concentration at time t and 
S is the sample volume: 
MC („J/min) = (c, * vj - c , „ * (Г,«. - y - S X (c 5 + . . . . + с г 4 0) 
240 X у/(С5 X Сгі0) 
The amount of dextran in the peritoneal cavity was divided by its concentration to calculate 
intraperitoneal volume (IPV,). The calculations of IPV0, IPV30 and IPV«, are shown below. IPV120, 
IPV180 and IPV240 were calculated in a similar way. 
I p v Ш ) _ I C . X V J - MC X Ъ X ^Съ X Сгі0) 
І р а Ш ) . C s х (IPV, -S) - MC χ 25 X ^ ( C 5 χ С2І0) 
'-зо 
JPV 6 0 (ml) = с зо * ( " У « - g) - MC x 30 χ ,/(C s χ С 2 4 0) 
C Í O 
The theoretical intraperitoneal volume (TIPV,), that is, the intraperitoneal volume in the absence of 
MC and sampling, was determined by adding the cumulative sample volume (St) and the MC: 
TIPVC (ml) = IPVC + Sc + MC χ t 
Transcapillary ultrafiltration (TCUF) was calculated by subtracting the initial theoretical 
intraperitoneal volume (TIPV5) from the theoretical intraperitoneal volume: 
n e t TCUFt (ml) = TIPVC - TIPVS 
Net ultrafiltration (UF) can be calculated or measured: 
net calculated UF (ml) = TCUFt - MC χ t 
net measured UF (ml) = V240 - V1 + St 
The pre-exchange residual volume (RVpre) and post-exchange residual volume (RV^,) were 
calculated with the equations below, in which V, is the inflow volume and C
r
 the dextran concen­
tration of the rinsing bag after drainage. 
Я V e (ЛІ) = V, Χ - ^ - ν1 
* W Uni) = Vz χ С*_ 
*
u 2 4 0 W 
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Summary 
In 16 children treated by CAPD recombinant human erythropoietin was administered 
intraperitoneally for the treatment of renal anaemia. The mean treatment period was 8.3 
months. Mean haemoglobin values increased from 4.9 mmol/I at start of therapy to 6.2 
after 6 months. While 11 out of 16 children needed a total of 22 transfusions during the 
6 months prior to therapy, no transfusions were needed after initiation of therapy. Patients 
started with a dose of 300 units/kg per week. After 6 months of therapy, the mean dose 
was 370 and after 12 months 279 units/kg per week. No major side-effects were observed. 
The incidence of peritonitis was not increased. We conclude that intraperitoneal 
administration of erythropoietin is effective in the treatment of renal anaemia in children 
treated by CAPD. 
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Introduction 
Intravenous and subcutaneous administration of erythropoietin has proven to be an 
effective treatment modality for renal anaemia in dialysis patients. In adult CAPD-patients 
erythropoietin is usually administered subcutaneously. Since injections create a con-
siderable psychological distress in young children treated with CAPD, intraperitoneal 
administration of erythropoietin would be preferable. We studied the effect of intraperi-
toneal erythropoietin in a group of children treated by CAPD. 
Patients and methods 
The study population consisted of children treated by CAPD for at least 2 months with 
mean haemoglobin values below 5.8 mmol/1 (1 mmol/1 = 16 g/1). Between November 1988 
and May 1990 16 children, 11 boys and 5 girls, entered the study. Median age of these 
children was 4.1 years (range 0.8 - 16.5). The children had been treated by CAPD for a 
median period of 20.5 months (range 2.5 - 70 months). In the 6 months prior to therapy 
11 out of 16 patients required a total of 22 transfusions. All patients started with a weekly 
dose of 300 units recombinant human erythropoietin (Recormon, Boehringer Mannheim 
GmbH, Almere The Netherlands) per kilogram body weight. Three times per week 
erythropoietin was given in 20 ml/kg of dialysis fluid (Dianeal 1.36 %, Baxter Inc., 
Deerfield, IL, USA) overnight in a 10-12 hour dwell period. The parents injected 
erythropoietin in the bags themselves. Before starting treatment the parents were carefully 
trained by a member of the nursing staff. A strictly aseptic technique was used. Dummy 
ampoules containing saline were used for teaching dissolving of the drug and injecting it 
into the dialysis bag. Training took about one hour, and was repeated if the parents or the 
instructing nurse were not certain about the familiarity with the procedure. The target 
haemoglobin level was 6.5 - 7.0 mmol/1. Dosage was adjusted every 2 months. As long 
as the target level was not reached erythropoietin dosage was increased by 75 units/kg per 
week. Dosage was decreased by 75 units if the haemoglobin concentration exceeded 7.0 
mmol/1. Haemoglobin, haematocrit and reticular cell counts were assessed every 2 weeks. 
Serum ferritin levels and transferrin saturation were assessed every 2 months. 
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Results 
The patients were treated for a period of 3 - 12 months. At the end of the study period six 
patients had been treated for a period of 12 months, 5 between 6 and 12 months and 5 for 
less than 6 months. In all patients haemoglobin values increased after start of therapy. 
Mean haemoglobin level was 4.9 mmol/1 at start of therapy, 5.8 after 3 months, 6.2 after 
6 months, and 6.7 after 12 months (Fig. 1). The highest reticulocyte counts of up to 67 
Hb (mmol/1) 
TIME (months) 
Figure 1. Blood haemoglobin levels during treatment with erythropoietin. Values are given 
as means + 1 standard deviation. N = number of patients studied. 
per thousand were seen in the first month of therapy. No patient required blood trans-
fusions after start of therapy. Mean erythropoietin dosage is depicted in Fig 2. After 6 
months of therapy the highest doses of erythropoietin were given. At that moment the 
mean dose was 370 (range 244 - 482) units/kg per week. After 12 months of therapy the 
mean dose was 279 (range 175 - 417). This reduction was not due to patient selection 
because the mean dose in patients who were treated for 12 months was also 370 units/kg 
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ЕГО (U/kg/week) 
9 12 
TIME (months) 
Figure 2. Dosage of erythropoietin during the treatment period. Values are given as means 
+ 1 standard deviation. N = number of patients studied. 
per week after 6 months of therapy. Oral iron therapy (ferrous chloride) was started when 
serum ferritin levels were below 100 μg/l. Only 4 out of 16 patients required iron therapy. 
In 11 patients who were treated for at least 6 months, we compared serum ferritin levels 
and transferrin saturation at the start of therapy to levels after 6 months of therapy. The 
geometric mean of the serum ferritin level was 221 μg/l prior to start of therapy and 129 
μg/l after 6 months of therapy (Wilcoxon Ρ < 0.01). Transferrin saturation was 0.37 ± 
0.15 before start of therapy and 0.30 ±0.10 after 6 months of therapy (not significant). 
In the study period a total of nine episodes of peritonitis occurred. The incidence of 
peritonitis was thus one every 14.7 patient months. A relationship between erythropoietin 
administration and peritonitis was suspected in one case only. In this child peritonitis 
occurred immediately after start of erythropoietin therapy. Ten out of 16 children did not 
suffer from peritonitis during the study period. In the 3 years before the study was 
performed (1987-1989) in our centre 28 peritonitis episodes were observed in 501 patient 
months (one episode every 17.9 patient months). The spectrum of the micro-organisms 
cultured did not change after introduction of erythropoietin. 
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Discussion 
Most children treated with haemodialysis are treated with intravenous erythropoietin at the 
end of dialysis, giving good results [1-3]. Good results have also been obtained with the 
intravenous treatment of children undergoing CAPD or CCPD [1,4]; this mode of therapy, 
however, is not practical. 
Subcutaneous administration of erythropoietin has been advocated since good 
therapeutic results have been obtained in several groups of patients with anaemia due to 
renal disease [1,5-8]. However, in young children treated by CAPD, subcutaneous 
injections will generally result in a struggle between the child and his/her parents. The 
administration of medication has been reported to contribute considerably to parental stress 
experiences [9]. 
For children treated by CAPD, intraperitoneal administration may be considered and has 
been advocated in the literature [10]. The amount of absorption of erythropoietin is, 
however, a point of discussion. In rabbits, an almost complete absorption from the 
peritoneal cavity was found [11]. In humans only a very limited absorption was observed 
[12-14]. Controversial results were obtained in therapeutic studies with intraperitoneal 
erythropoietin [10,13,15,16]. 
Since the absorption of erythropoietin was assumed to be inversely correlated with the 
quantity of dialysis fluid used for instillation, it was decided to halve the amount of 
dialysis fluid [11]. It was not chosen to instill the erythropoietin undiluted, since this 
would implicate that the patient would not be dialysed for a period of 12 hours. Since 
erythropoietin will be mainly absorbed by the lymphatics, and lymphatic absorption has 
been reported to be higher in children than in adults [17], a sufficient absorption was 
expected and established (unpublished observations). 
There are no unanimous data on the dosages needed for the treatment with erythropoie-
tin. In a large study on intravenous administration in adult haemodialysis patients a median 
weekly dose of 200 units/kg was adequate [18]. Subcutaneous administration generally 
allows lower dosages: the literature provides data ranging from 84 to 120 units/kg per 
week for adult patients during the maintenance phase [6,13]. In a paediatric study the 
mean dose needed was 210 units/kg per week [7]. Larger doses are needed if erythro-
poietin is applied intrapcritoneally. Frenken et al. used a maintenance dose of 216 units/kg 
per week in adult patients [10], whereas our study needed 279 units/kg per week in 
children after 1 year of treatment. The time from start of treatment to achievement of 
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target range was about 9 months in our study (see Fig. 1). This is relatively long, but 
acceptable since no blood transfusions were necessary after start of erythropoietin therapy. 
Contamination is a risk if medication is added to the dialysis fluid. Indeed, a high 
incidence of peritonitis in strong association with erythropoietin administration has been 
reported in children as well as in adults [19,20]. We believe, however, on the basis of the 
results presented in this study, that careful training of the parents can minimise the risk 
of peritonitis. The peritonitis incidence in the study population was one every 14.7 patient 
months, which is low when compared with literature data of paediatric series and is similar 
to our experience in previous years [21,22]. 
Other side effects of the therapy were only of minor importance. Seizures were not 
observed in our patients. Hypertension was not a major problem in our population, 
although two children needed minor adjustment of their antihypertensive medication. Only 
4 out of the 16 patients needed iron supplementation. This is low compared to the 
literature [23]. The explanation is the iron overload present in most children at the start 
of erythropoietin therapy due to multiple blood transfusions. In the future, when erythro-
poietin will be started before transfusions are needed, most patients will require iron 
supplements. 
In conclusion, since the incidence of peritonitis is not increased and the training 
procedure is not very costly or time-consuming, intraperitoneal administration of 
erythropoietin is the preferred mode of treatment in young children on CAPD. The 
advantages with respect to patient and parent acceptance will compensate for the somewhat 
higher costs. 
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Summary 
In children treated by continuous ambulatory peritoneal dialysis (CAPD) renal anaemia is 
preferably treated by intraperitoneal administration of erythropoietin, since subcutaneous 
administration is painful and frightening for the child. Pharmacokinetics of erythropoietin 
were studied in three groups of children treated by CAPD. In group subcutaneous (SC) 
(n=5) erythropoietin was administered subcutaneously, whereas in group intraperitoneal 
1 (IP1) (n=8) and intraperitoneal 2 (IP2) (n=8) erythropoietin was given intraperitoneally 
during a 12-hour dwell. Group IP1 received erythropoietin in 20 ml/kg of dialysis fluid, 
while in group IP2 the hormone was added to only 50 ml of dialysate, irrespective of body 
weight. The median area under the curve (AUC) was 4064 mU.hr/ml (range 2647-24357) 
in group SC, 1698 (570-5514) in group IP1 and 3577 (1225-6555) in group IP2. In com-
parison to group SC the AUC was significantly lower in group IP1 (Wilcoxon; P=0.02). 
The difference between group SC and group IP2 was not statistically significant. It can 
be concluded that in children on CAPD the resorption of erythropoietin after intrape-
ritoneal administration, measured as AUC, is similar to subcutaneous administration, when 
erythropoietin is administered in 50 ml of dialysate. The dose needed to treat renal 
anaemia with erythropoietin administered intraperitoneally this way will have to be 
established in a therapeutic study. 
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Introduction 
In a previous study we have shown that intraperitoneal administration of erythropoietin is 
an effective treatment modality in children on continuous ambulatory peritoneal dialysis 
(CAPD) [1]. We prefer this application route because the alternative, subcutaneous 
administration (SC), is painful and frightening for the child. A disadvantage of 
intraperitoneal administration (IP) is the higher maintenance dose with higher expense as 
a consequence [2]. In the clinical setting, erythropoietin is usually added to a bag of 
dialysate containing the normal amount or half of the normally used amount of dialysis 
fluid [1,3,4]. However, the bioavailability of intraperitoneally administered erythropoietin 
is greatly improved when erythropoietin is given undiluted [5]. In this study pharmacoki-
netics of erythropoietin were studied in a group of children treated with CAPD. 
Subcutaneous administration was compared to intraperitoneal administration in half of the 
normally used amount and to intraperitoneal administration in a minimal amount of 50 ml 
of dialysis fluid. 
Patients and methods 
Pharmacokinetics were studied in three groups of patients. All patients received 100 units 
of recombinant human erythropoietin (Recormon, Boehringer Mannheim GmbH, Almere 
The Netherlands) per kilogram body weight at TO. 
Group SC consisted of 5 children, 2 girls and 3 boys. The median age of these children 
was 7.3 years (range 1.8-10.4) and they had been on CAPD for a median period of 0.7 
months (range 0.1-86.8). Causes of endstage renal disease were: posterior urethral valves, 
renal dysplasia, polycystic kidney disease (adult type) and unknown (2). Erythropoietin 
was administered subcutaneously at TO. 
Group IP1 included 8 children, 2 girls and 6 boys. Median age was 3.4 years (range 
0.6-12.5) and the patients had been on CAPD for a median period of 18.3 months (range 
2.7-52.3). Causes of renal failure were: posterior urethral valves (2), renal dysplasia (2), 
haemolytic uraemic syndrome, polycystic kidney disease (adult type), Alport syndrome and 
brachio-oto-renal syndrome. Erythropoietin was administered intraperitoneally overnight 
from TO to T12 in 20 ml/kg dialysis fluid (Dianeal 1.36 %, Baxter Inc., Deerfield, IL, 
USA), which is half of the normally used amount. Dialysis fluid was removed from a bag, 
so that it would contain 20 ml/kg. A 250 ml bag was used in 6 patients. In the other 2 
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Figure I. Median erythropoietin levels (mU/ml) versus time (hours) in three groups of 
patients. In group SC erythropoietin was administered subcutaneously, in group IP1 
intraperitoneal!у in 20 ml/kg of dialysate and in group IP2 in 50 ml of dialysis fluid. 
patients a 375 and a 500 ml bag was used respectively. At T12 the abdomen was drained 
and filled with the usual amount of about 40 ml/kg dialysis fluid. 
There were also 8 children in group IP2, 1 girl and 7 boys. Their median age was 8.2 
years (range 3.3-14.1) and median length of CAPD treatment 0.8 months (range 0.2-88.8). 
Underlying renal diseases were: posterior urethral valves (2), renal dysplasia (2), 
haemolytic uraemic syndrome (2), cystinosis and congenital nephrotic syndrome. In this 
group erythropoietin was administered from TO to T12 in 50 ml of dialysis fluid, 
irrespective of the weight of the patient. A 250 ml bag was used, from which 200 ml was 
removed. At T12 the abdomen was not drained, but immediately filled with 40 ml/kg 
dialysis fluid. 
Blood samples were collected at TO, T4, T8, T12, T18, T24, T36 and in group SC also 
at T48. The samples were centrifuged and stored at a temperature of- 20 °C. Erythropoie­
tin levels were determined by radioimmunoassay [6]. 
SC 
IP1 
IP2 
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The area under the curve (AUC) was calculated by trapezoidal fit, with subtraction of 
the area represented by the baseline value at TO. The AUC was determined from TO to 
T36 in groups IP1 and IP2 and from TO to Too in group SC. In this group the AUC was 
calculated by trapezoidal fit from TO to T48 and by the method of Benet and Galeazzi 
from T48 to T°o [7]. 
Statistical comparisons between the groups were performed using the chi-square test and 
the Wilcoxon test. 
Results 
There were no statistically significant differences between the three groups with respect 
to age and sex. Median erythropoietin level versus time is plotted in figure 1. for all three 
patient groups. The highest peak levels were seen in group IP2 at the end of the 12 hour 
dwell. 
The AUC from TO to T36 was 1698 (range 570-5514) mU.hr/ml in group IP1 and 3577 
(range 1225-6555) in group IP2. In group SC the AUC extrapolated from TO to Too was 
4064 (range 2647-24357). Thus, in comparison to subcutaneous administration, resorption, 
measured as AUC, was 42 % in group IP1 and 88 % in group IP2. In comparison to 
group SC the AUC was significantly lower in group IP1 (Wilcoxon; P=0.02). The 
differences between group SC and group IP2 and between group IP1 and IP2 were not 
statistically significant. 
Discussion 
Renal anaemia can be effectively treated with erythropoietin [8]. This also applies to 
children with renal failure [1,9-15]. In patients treated with CAPD, subcutaneous 
administration once or twice a week seems to be the most effective treatment modality 
[8,16-20]. Dosage during the maintenance phase is approximately 100-150 units/kg per 
week in adult patients [8]. In children a mean maintenance dose of 102 to 210 units/kg 
per week has been reported [12,15]. The mean age of the children in these studies 
exceeded 10 years. CAPD is the first choice treatment especially in young children with 
chronic renal failure. There seems to be an influence of age on the dosage needed; in a 
multicentre study by Scigalla et al. [21] in children on haemodialysis the maintenance dose 
was 326 units/kg per week in the youngest age group (< 5 years), whereas it was only 128 
units/kg per week in the oldest age group (> 15 years). 
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Subcutaneous administration of erythropoietin is painful, although there are differences 
between different brands of erythropoietin [22-24]. For this reason and because subcu-
taneous administration considerably increases the burden placed on the parents, we prefer 
to administer erythropoietin intraperitoneally in children treated with CAPD [1]. 
Erythropoietin is absorbed from the peritoneal cavity [5,25]. Biological availability is 
primarily determined by the amount of dialysis fluid to which erythropoietin is added 
[5,25]. Some therapeutic studies have established that intraperitoneal administration of 
erythropoietin is in fact an effective treatment modality [1,3,4,26]. In adult patients the 
mean maintenance dose was 225 - 255 units/kg per week [3,4]. In a former study by our 
group a mean maintenance dose of 279 units/kg per week was needed in children [1]. In 
these studies erythropoietin was added to a bag of dialysate containing the normal amount 
[4,26] or half of the normally used amount of dialysis fluid [1,3]. When erythropoietin is 
administered intraperitoneally this way, the dose needed is high in comparison to 
subcutaneous administration. A relatively high dose of this expensive drug leads to higher 
costs [2]. For this reason it is important to look for ways of improving absorption of 
intraperitoneally administered erythropoietin. 
In this study pharmacokinetics of subcutaneous administration were compared to two 
different modes of intraperitoneal administration. One group of patients received 
erythropoietin in 20 ml/kg of dialysis fluid, which is half of the normally used amount of 
40 ml/kg. This procedure was also used in the therapeutic study published previously [1]. 
The other group received erythropoietin in 50 ml of dialysate, irrespective of body weight. 
Erythropoietin was added to a bag of dialysis fluid because this would be practical in the 
event of a future therapeutic study. Administering erythropoietin undiluted and 
subsequently flushing the catheter line for instance would imply extra manipulation and 
consequently increase peritonitis risk. Since the dead space of the catheter and connecting 
line is approximately 13 ml, adding erythropoietin to a smaller amount than 50 ml of 
dialysis fluid would mean that less than 75 % of the administered dose is in the abdominal 
cavity during the dwell. Since the abdomen is not drained the following morning the 
erythropoietin in the dialysis line will eventually reach the abdominal cavity, diluted of 
course in 40 ml/kg dialysis fluid. 
At the start of the dwell the amount of fluid in the abdominal cavity containing the 
administered dose of erythropoietin will be the sum of the administered volume plus the 
residual volume. Residual volume varies considerably between patients and can exceed 200 
ml [27]. Studies on fluid kinetics in children indicate that a few hundred millilitres of 
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dialysis fluid can be removed by lymphatic absorption during a 12 hour dwell even in 
small children [27]. 
The AUC was calculated in all study groups as a measure for resorption. The AUC was 
estimated to Too in patients who received erythropoietin subcutaneously using a pharmaco-
kinetic model [28]. This was done because erythropoietin levels tend to be above baseline 
beyond the study period of 48 hours in this patient group. Extrapolation of the AUC to 
infinity in patients who were given erythropoietin intraperitoneally was not possible, 
because this mode of administration cannot be described by a simple pharmacokinetic 
model. Because of this the AUC is slightly underestimated in these patients. 
Median resorption was only 42 % when compared to subcutaneous administration in 
the group that received erythropoietin intraperitoneally in half of the normally used amount 
of dialysis fluid. The difference in resorption between subcutaneous and this mode of 
intraperitoneal administration is statistically significant. This is compatible with the 
relatively high dose needed in therapeutic studies [1,3]. Resorption was 88 % when 
compared to subcutaneous administration in the group to whom erythropoietin was given 
intraperitoneally in 50 ml of dialysate. 
In vitro studies have established that erythropoietin adheres to the wall of a dialysis bag 
[29]. One could argue that absorption of erythropoietin is lower in the group that received 
erythropoietin intraperitoneally in half of the normally used amount of dialysis fluid, 
because more erythropoietin is lost sticking to the wall of the bag. In the group that 
received erythropoietin in 50 ml of dialysis fluid a 250 ml bag was used, from which 200 
ml was removed. In the group in which erythropoietin was added to 20 ml/kg of dialysate 
the bag used depended naturally upon the weight of the patient, but this was also a 250 
ml bag in 6 out of 8 patients. Since the same bag was used in most cases, it seems 
unlikely that the difference in resorption between the two intraperitoneal groups, measured 
as AUC, was caused by the fact that different amounts of erythropoietin were lost, sticking 
to the wall of the plastic bag. 
There are several studies that compare pharmacokinetics of erythropoietin administered 
subcutaneously and intraperitoneally [28,30-34]. In one of these studies a much higher 
dose of erythropoietin was given intraperitoneally, making interpretation difficult [34]. In 
three studies in adult patients erythropoietin was added to the normal amount of 2 litres 
of dialysis fluid [31-33]. Dwell times of 4, 8, 10 and 12 hours were used and the AUC 
from 0 to 24 hours was between 24 % and 56 % when compared to subcutaneous 
administration. One study was performed in children [28]. In this study three children were 
given erythropoietin intraperitoneally during 12 hours in 100 ml of dialysis fluid. The 
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AUC was 43 % when compared to 9 children who received the same dose subcutaneously. 
This seems rather low when compared to the results of our study. 
The fact that resorption of erythropoietin administered intraperitoneally in 50 ml of 
dialysate is similar to resorption of subcutaneously administered erythropoietin does not 
automatically mean that dosage in a therapeutic study will be similar. Subcutaneous 
administration is very effective because the serum erythropoietin concentration is sustained 
above clinically effective levels much longer [35]. Animal studies demonstrate that 
erythropoietin administered by repeated injections of small amounts produces a greater 
degree of erythropoiesis than a single injection of an equal total dose [36]. It is however 
probable that the dosage will be lower when erythropoietin is administered intraperitoneal-
ly in 50 ml instead of 20 ml/kg. The actual dose will have to be determined in a thera-
peutic study. 
We conclude that in children on CAPD the resorption of erythropoietin after intrape-
ritoneal administration, measured as AUC, is similar to subcutaneous administration, when 
erythropoietin is administered in a small volume of dialysate. The dose needed to treat 
renal anaemia with erythropoietin administered this way will have to be established in a 
therapeutic study. 
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Summary 
Classical (CH50) and alternative (AP50) complement activity and serum levels of factors 
Clq, C3, C4, C3d, B, D and Ρ in С APD patients were compared to normal controls and 
to children with preterminal renal failure. A group of 22 children on CAPD was compared 
to a normal control group of 44 children and to a group of 12 children with preterminal 
renal failure with a creatinine clearance below 25 ml/min/1.73 m2. CH50, AP50, C3 and 
В were not significantly different from the control group in both the CAPD and 
preterminal groups. Factors Clq (P = 0.01) and C4, C3d, D and Ρ (P < 0.001) were higher 
in the CAPD group in comparison to the normal control group. The factors D (P < 0.001) 
and Ρ (P = 0.02) were also elevated in the preterminal group. For the measured factors 
there was no significant difference between the CAPD group and the preterminal group. 
It is concluded that there is no deficiency of complement in children treated with CAPD. 
High levels of C3d and D can be explained by reduction of their elimination by the 
kidney. The increased levels of the other factors are presumably due to increased synthesis 
in renal failure. This does not seem to be caused by CAPD. 
122 
SERUM LEVELS 
Introduction 
In continuous ambulatory peritoneal dialysis (CAPD) patients proteins are removed with 
the dialysis solution. In patients with nephrotic syndrome it was suggested that an 
increased incidence of severe infections may be the result of the loss of alternative 
pathway components of the complement system, particularly factor В [1]. On the other 
hand increased factor D and C3d concentrations have been reported in chronic renal 
failure, due to reduced renal catabolism [2,3]. 
Complement factors are important for opsonization and killing of bacteria entering the 
peritoneal cavity [4,5]. A decreased opsonic activity of peritoneal fluid is related to a high 
peritonitis rate [6]. 
In this study we determined the effect of CAPD on the classical and alternative 
pathways of the serum complement system in a group of children treated with CAPD. 
Patients and methods 
We studied 22 children, 8 girls and 14 boys, treated with CAPD and without significant 
infections a few weeks before or after the study. Median age was 7.2 years, with a range 
of 2.1 to 17.1 years. They had been on CAPD for a median period of 17.0 months (range 
0.4 - 89.1 months). Urinary creatinine clearance was below 5 ml/min/1.73 m2 in all 
patients. Urine volume varied from 0 (6 patients) to approximately 1000 ml/24 hr. 
Underlying renal diseases are listed in Table 1. The children treated with CAPD were 
compared to a group of healthy children (normal controls) and to a group of children with 
preterminal renal failure. 
The normal controls consisted of 44 children, 21 girls and 23 boys who were seen for 
various reasons in a general paediatric outpatient clinic. Children in whom bloodsampling 
was indicated for one reason or another were considered suitable as controls if they had 
no infection or other diseases in which complement activation could be suspected. The 
median age of these children was 7.7 years, with a range of 1.2 to 16.0 years. 
The group with decreased renal function, conservatively treated, consisted of 12 
children, 4 girls and 8 boys. Median age of these children was 7.6 years, with a range of 
1.4 to 11.4 years. The calculated median creatinine clearance of these children was 16 
ml/min/1.73 m2 (range 6 - 24). Original renal diseases are listed in Table 1. 
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Posterior urethral valves 
Renal hypoplasia/dysplasia 
Glomerulosclerosis 
Polycystic kidney disease (adult type) 
Haemolytic uraemic syndrome 
Nephronophtisis 
Cystinosis 
Hyporeninemic hypoaldosteronism 
Branchio-oto-renal syndrome 
Bartter syndrome 
Ischaemic nephropathy 
Unknown 
preterminal 
3 
3 
1 
I 
1 
2 
1 
CAPD 
3 
7 
3 
1 
2 
1 
1 
1 
1 
2 
Table 1. Causes of endstage renal disease in the CAPD group (n=22) and the preterminal 
group (n=12). 
Informed consent was obtained from the parents of all patients after explanation of the 
purpose and methods of the study. Samples of coagulated blood were collected in ice, cen-
trifuged at 4 CC, and immediately frozen at a temperature of - 70 °C. 
Haemolytic titrations of CH50 were performed with optimally sensitized sheep 
erythrocytes using appropriately diluted serum samples as described previously [7,8]; AP50 
was assessed using freshly obtained rabbit erythrocytes as described before [9], while Clq, 
C4, C3 and В were assessed by radial immunodiffusion using monospecific polyclonal 
rabbit antisera [9]. Factor D was assessed functionally with D-deficient human serum and 
rabbit erythrocytes [7]. factor Ρ (Properdin) was measured by ELISA using monospecific 
rabbit antiproperdin antiserum. Factor C3d was determined as follows: 100 μΐ of fresh 
frozen serum was treated with a final concentration of 10 percent polyethylene glycol for 
1 hour at 0 °C and centrifuged for 10 minutes at 3000 rpm at 4 °C. The supernatant was 
assessed for C3d content by rocket electrophoresis. The antiserum used was a mono­
specific polyclonal goat antibody against C3d, prepaired by immunisation with purified 
C3d. A standard with known contents of C3d was included in each assay. The role of the 
measured factors in the complement system are illustrated in figure 1. 
Statistical comparisons between the groups were performed using the chi-square-test, 
the two-sample t-test or the Wilcoxon test. Any Ρ values less than 0.03 were considered 
significant. 
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Figure 1. The classical (upper part of the figure) and alternative (lower part of the figure) 
pathway of the complement system. The factors studied are indicated in boldface. 
Results 
For age and sex there were no statistically significant differences between the three groups. 
Complement activity and levels of components in the three groups are compared to each 
other in figure 2. Age dependency of these values was not seen in any group. 
Total classical complement activity (CH50) was significantly higher in the CAPD group 
(mean 424 U/mL) when compared to the preterminal group (mean 290 U/mL; Ρ = 0.02). 
Total alternative complement activity (AP50) did not differ significantly between the three 
groups. 
There was a statistically significant difference in the measured specific components of 
the classical pathway (Clq, C3, C4, C3d) between the CAPD group and the normal 
control group for Clq, C4 and C3d. These three components were higher in the CAPD 
group. The Clq level was only slightly elevated (mean 14.4 mg/dL in CAPD patients and 
12.6 mg/dL in controls; Ρ = 0.01). C4 and especially C3d levels were markedly elevated. 
Mean C4 level was 42.8 mg/dL in CAPD patients and 26.9 mg/dL in controls (P < 0.001). 
The median C3d level was 10.0 /tg/mL in CAPD patients and 6.0 μg/mL in controls (P 
< 0.001). For the components of the classical pathway there were no significant 
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Figure 2. Results of CH50, AP50, Clq, C3, C4, В and D (mean ± 1 standard deviation) and 
C3d and Ρ (median and range) in the control group (C), the preterminal group (P) and the 
CAPD group (D). Any Ρ values less than 0.03 were considered significant and are indicated 
in the figure. 
differences between the preterminal group and the normal control group and between the 
preterminal group and the CAPD group. 
There was a statistically significant difference in the measured components of the 
alternative pathway (B, D, and P) between the CAPD group and the normal control group 
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for factors D and Ρ (Ρ < 0.001). The mean factor D level was 104.3 U/mL in CAPD 
patients, whereas it was only 6.2 U/mL in the controls. The median Properdin level was 
20.8 μg/mL in CAPD patients and 16.0 /xg/mL in controls. In the preterminal group factor 
D (mean 85.6 U/mL; Ρ < 0.001) and factor Ρ (median 19.3 Mg/mL; Ρ = 0.02) were also 
significantly higher when compared to the normal control group. For the components of 
the alternative pathway there were again no significant differences between the CAPD 
group and the preterminal group. 
Discussion 
Peritonitis is still a major complication of CAPD-treatment in adults and children [10-13]. 
The presence of a catheter in the peritoneal cavity as well as defects in host defence 
contribute to this complication [14-17]. The dialysate within the peritoneal cavity is 
exchanged several times every day. Phagocytic cells and opsonins are constantly removed 
from the peritoneal cavity, and the phagocytic function of peritoneal macrophages is 
impaired [18,19]. Complement factors are important for opsonization and killing of 
bacteria entering the peritoneal cavity [4-6]. During CAPD these factors are continuously 
removed from the body, like other proteins. In fact, there may be a large and variable loss 
of proteins in CAPD [20-27]. In 11 of 12 young children treated with CAPD, IgG2 levels 
were not detectable, presumably due to loss in the peritoneal dialysis fluid [28]. This 
might compromise host defence in these children. In patients with the nephrotic syndrome 
decreased factor В concentration, due to loss in the urine, is associated with decreased 
serum opsonic activity [1]. Complement deficiencies could theoretically occur in CAPD 
patients. 
In our study loss of complement factors in children on CAPD apparently does not lead 
to complement deficiencies in serum. We found high levels of several complement factors 
in serum of CAPD patients. Two mechanisms could account for these high levels: 
decreased elimination or increased production. 
In our CAPD patients levels of Clq, C4, C3d, Ρ and especially of factor D are high 
when compared to a healthy control group. However, in comparison to a group of patients 
with preterminal renal failure the levels are not elevated. The molecular weights of C3d 
and D are low compared to the other factors (Table 2.). Indeed previous studies in patients 
with chronic renal failure have shown that elevation of C3d and D is probably caused by 
impaired renal handling [2,3]. These low molecular weight proteins are thought to be 
catabolized by the kidney after glomerular filtration and tubular reabsorption [29,30]. It 
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Clq 460 
C4 205 
C3 185 
C3d 30 
В 93 
D 24 
Ρ 220 
Table 2. Molecular weights of the complement factors studied (kD). 
cannot be excluded that an altered catabolism by the liver may also play a role. 
The dialysate/plasma ratio of C3d and D is approximately 0.01 after a 6-hour dwell 
[2,31]. However high serum concentrations can cause levels of factor D in peritoneal fluid 
to be similar to those in normal human serum [31]. It is not clear what the consequences 
are of accumulation of complement components in peritoneal fluid. It has been suggested 
that high levels of factor D might lead to a more efficient opsonization [32,33]. 
Elevation of Clq and Ρ and the striking elevation of C4 probably cannot be caused by 
impaired renal elimination. The proteins Clq, Ρ and C4 are proteins too large to be 
filtered at the glomerulus in significant amounts. Renal extraction of large proteins is 
considered to be insignificant [34]. Since complement factors are acute phase proteins, one 
could assume an acute phase reaction in these patients. However in a group of 10 children 
treated with CAPD without significant infections, the level of C-reactive protein was never 
elevated (own data, not published). An increased production of Clq, C4 and Ρ in response 
to complement activation is a possibility. In fact, it has been suggested that there might 
be chronic activation of complement in patients treated with CAPD. The indwelling 
peritoneal catheter and stimulation by the dialysis fluid were considered as possible causes 
[35,36]. Complement activation however is probably not CAPD-related since an elevation 
of high molecular weight complement components, particularly of factor P, was also seen 
in the group of children we studied with chronic renal failure not treated with renal 
replacement therapy. 
In conclusion, there is no deficiency of serum complement in children treated with 
CAPD. High levels of low molecular weight complement factors, especially factors D and 
C3d in children treated with CAPD can be explained by a decreased or absent renal 
elimination. High levels of high molecular weight components seem to be the result of 
increased production, possibly in response to chronic activation of complement. This, 
however, is not specific for CAPD patients, since it is also observed in children with 
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preterminal renal failure. Studies with labelled complement components in combination 
with an assessment of degradation products of complement could give a definitive answer 
about the possibility of an increased synthesis of these components. 
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Summary 
During continuous ambulatory peritoneal dialysis (CAPD) activation of complement in the 
peritoneal cavity may theoretically occur, with inappropriately high or low levels of certain 
complement factors in dialysate as a consequence. In a group of 14 children on CAPD, 
with a median age of 7.8 years (range 2.1 -13.2), it was tested whether levels of a number 
of complement factors in dialysate were in the range that was predicted on the basis of 
their molecular weight. Serum and dialysate levels of Clq, C3, C4, C3d, B, D and Ρ were 
measured after a night dwell. Simultaneously four non-complement proteins ^-micro­
globulin, albumin, IgG and cc2-macroglobulin) were also measured in dialysate and serum. 
Assuming a linear relationship between the log base 10 of the dialysate/serum ratio of 
these non-complement proteins and the log base 10 of their molecular weight, the expected 
ratios of all complement factors were determined. The differences between actual and 
predicted ratios were tested using a modified t-test, taking into account the inaccuracy of 
the estimate. The ratios of factor D (p<0.001) and C3d (p=0.035) were elevated, whereas 
those of C3 (pO.001), C4 (pO.001) and factor Ρ (p=0.012) were decreased. Relatively 
low dialysate/serum ratios of C4, C3 and factor Ρ could be caused by intraperitoneal 
consumption of complement. High levels of C3d are compatible with this. High 
dialysate/serum ratios of factor D indicate intraperitoneal production of factor D. These 
results provide evidence for activation of complement in the peritoneal cavity in children 
on CAPD. A further reduction of already low levels of complement factors in dialysate 
as a result of this may impair host defence. 
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Introduction 
It has been suggested that there might be chronic activation of complement in patients 
treated with continuous ambulatory peritoneal dialysis (CAPD). The indwelling peritoneal 
catheter and stimulation by the dialysis fluid were considered as possible causes [1,2]. In 
a previous study, we found high serum levels of the complement factors Clq, C4, C3d, 
D, and Ρ in children treated with CAPD, and high levels of factors D and Ρ in children 
with preterminal renal failure, when compared to a normal control group [3]. High levels 
of low molecular weight complement factors, particularly factor D and C3d, in children 
treated with CAPD can be explained by a decreased or absent renal elimination [4-6]. 
High levels of high molecular weight components seem to be the result of increased 
production, possibly in response to chronic activation of complement. This is not specific 
for CAPD patients, since it is also observed in children with preterminal renal failure. 
If CAPD is responsible for activation of complement in the peritoneal cavity, local 
production or consumption of complement factors would be a possibility. In this study, 
dialysate levels of complement factors were judged in relation to their serum concentra­
tion, assuming that the main determinant of dialysate concentration is molecular weight, 
if proteins are not produced or consumed in the peritoneal cavity. 
Patients and methods 
We studied 14 children (4 girls and 10 boys) treated with CAPD. The patients had no 
exit-site infections or peritonitis for at least one month prior to the study. They had not 
been treated with antibiotics for at least 2 weeks. Median age was 7.8 years, with a range 
of 2.1 - 13.2 years. They had been on CAPD for a median period of 42.4 months (range 
0.4 - 89.1). Urinary creatinine clearance was below 5 mL/min/1.73 m2 in all patients. 
Urine volume varied from 0 (2 patients) to approximately 1000 mL/24 hours. Underlying 
renal diseases were: posterior urethral valves (3 patients), renal hypoplasia/dysplasia (3 
patients), unknown (2 patients). And, polycystic kidney disease (adult type), haemolytic 
uraemic syndrome, nephronophthisis, cystinosis, hyporeninaemic hypoaldosteronism, and 
branchio-oto-renal syndrome were found in 1 patient each. Informed consent was obtained 
from the parents of all patients after explanation of the purpose and methods of the study. 
In the morning, immediately after an overnight dwell of approximately 10 hours with 
dialysate containing 1.36 % glucose (Dianeal 1.36 %, Baxter Inc., Deerfield, IL), the 
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patients visited our out-patient clinic. Samples of coagulated blood were collected on ice, 
centrifuged at 4 °C, and immediately frozen at a temperature of- 70 °C. Dialysate samples 
were collected in a tube containing bovine serum albumin (BSA) (Brunschwig, 
Amsterdam) in a final concentration of 2 %. This BSA did not contain proteins that 
cross-reacted with anti-human complement antisera. In addition, the BSA was free of 
factor D haemolytic activity. 
Determinations of Clq, C3, C4, C3d, B, D, and Ρ in serum were performed as 
described previously [3]. Methods of determination of C3d, D, and Ρ were the same in 
dialysate and serum. Dialysate Clq, C3, and В were assessed by ELISA. C4 was 
determined in dialysate, just as in serum, by radial immunodiffusion. In dialysate, 
however, determination was preceded by freeze drying and subsequent solubilization in 
one tenth of the original volume. Albumin, IgG, and a2-macroglobulin were determined 
by turbidimetry; ß2-microglobulin by radio immuno assay. 
It was assumed that the four non-complement proteins measured in this study are not 
produced or consumed in the peritoneal cavity. It was also assumed that during a specific 
dwell in a specific patient dialysate concentration is a function of serum concentration and 
molecular weight. Possible effects of molecular structure or charge were neglected. 
For each individual patient, least squares regression was performed using the results of 
the 4 non-complement proteins. The log base 10 of the dialysate/serum ratio (logI0[R]) was 
used as the dependent variable and the log base 10 of the molecular weight (logi0[W]) as 
the independent variable. The assumption of a linear relationship between log10[R] and 
log,0[W] was checked with the Pearson correlation coefficient. With these regression lines 
a predicted log10[R] was determined for each complement factor in each patient. Predicted 
and measured log,0[R]s were subtracted. The differences were tested for significance per 
complement factor using a modified t-test, taking into account the inaccuracy of the 
prediction. A full description of this modification is given in the appendix. Any ρ values 
less than 0.05 were considered significant. 
Results 
The correlation coefficients for the relation between log]0[R] and log10[W] were smaller 
than -0.95 in all patients, with ρ values below 0.05, confirming a linear relationship 
between the two. 
The dialysate/serum ratios of the complement factors versus molecular weight are given 
in figure 1. A double-logarithmic scale is used, and the expected relation between 
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molecular weight and ratio, based on measurements of ß2-microglobulin, albumin, IgG, 
and a2-macroglobulin, is indicated as a reference line. 
ratio dialysate serum (%) 
100 
10 
10 100 1,000 
molecular weight (kiloDalton) 
Figure 1. The dialysate/serum ratios (mean ± 1 SD) of Clq (τ), C4 (A), C3 (•), C3d (•), 
В (ж), D (χ) and Ρ (χ) versus molecular weight. A double-logarithmic scale is used, and the 
expected relation between molecular weight and ratio, based on measurements of β2-
microglobulin, albumin, IgG and a2-macroglobulin, is indicated as a reference line. 
The serum and dialysate levels and the actual and predicted dialysate/serum ratios of 
the measured complement factors are listed in table 1. The ratios of factor D (pO.001) 
and C3d (p=0.035) were elevated, whereas those of C3 (p<0.001), C4 (pO.001), and 
factor Ρ (p=0.012) were decreased. It must be noted that the standard deviation was rather 
high for factor D. 
Discussion 
Complement factors are important for opsonization and killing of bacteria entering the 
peritoneal cavity [7,8]. A decreased opsonic activity of peritoneal fluid is related to a high 
peritonitis rate [9]. 
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Clq 
C4 
C3 
C3d 
В 
D 
Ρ 
dialysate level 
1.9 ± 0.8 μ§/ιπί 
5.3 ± 4.0 /ig/mL 
10.7 ± 5.6 /tg/mL 
2.1 ± 0.7 ng/mL 
8.2 + 3.6 /ig/mL 
40.1 ± 32.3 U/mL 
328.9 ± 149.9 ng/mL 
serum level 
14.9 ± 3.0 
49.6+ 13.6 
69.6 ± 12.3 
17.4 ± 12.4 
17.2 ± 3.3 
107.3 ± 24.4 
20.4 ± 2.3 
mg/dL 
mg/dL 
mg/dL 
μg/mL 
mg/dL 
U/mL 
Mg/mL 
ratio (%) 
1.3 + 0.7 
1.0 ± 0.6 ' 
1.5 ± 0.6 * 
15.1 ± 6.5 ' 
4.7 ± 1.5 
37.7 ± 32.3 ' 
1.6 ± 0.8 ' 
predicted 
ratio (%) 
1.1 ±0.4 
2.2 + 0.8 
2.4 ± 0.9 
12.0 ± 5.0 
4.4 ± 1.7 
14.6 ± 6.2 
2.0 ± 0.8 
Table 1. The dialysate and serum levels of Clq, C4, C3, C3d, B, D and Ρ (mean ± 1 SD) and 
actual and predicted dialysate/serum ratios. A significant difference between actual and 
predicted dialysate/serum ratios is indicated with an asterisk. See text for the exact ρ values. 
Theoretically, intraperitoneal production and consumption of complement factors can 
occur in stable CAPD patients without peritonitis. An inappropriately high or low 
dialysate/serum ratio could be the result of this. Some studies produced evidence for 
activation of complement during CAPD. Lewis et al. found a decreased C5a receptor 
availability on peripheral blood neutrophils and monocytes in CAPD patients, indicating 
continuous exposure of these cells to C5a [1]. It was postulated that this was the result of 
continuous complement activation, possibly caused by the indwelling peritoneal catheter 
or by continual chemical stimulation of the dialysate. Holmes et al. reported periodic 
elevations of C3bi in dialysate in 2 out of 8 CAPD patients, not associated with peritonitis 
[2]. Young et al. measured a number of complement components in serum and dialysate 
and found high dialysate/plasma ratios of Bb, iC3b, and SC5b-9, and possibly of C4d [10]. 
It was concluded that complement activation occurs during CAPD, mainly by the 
alternative pathway. Krediet et al., however, simultaneously measured serum and dialysate 
levels of C3d and reported that there was no evidence for production in the peritoneal 
cavity [4]. 
In a previous study, we established high serum levels of Clq, C4, C3d, D, and Ρ in 
children on CAPD, and high serum levels of D and Ρ in children with preterminal renal 
failure, when compared to normal controls [3]. The molecular weights of C3d and D are 
low compared to the other factors (Table 2.). High levels of these low molecular weight 
complement factors C3d and D can be explained by reduction of their elimination by the 
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Clq 460 
C4 205 
C3 185 
C3d 30 
В 93 
D 24 
Ρ 220 
Table 2. Molecular weights of the complement factors studied (kD). 
kidney. The increased levels of the other factors were presumed to be the result of 
increased synthesis. This effect seemed to be related to renal failure and not specific for 
CAPD patients. 
If CAPD as such promotes complement activation, one would expect this to take place 
in the peritoneal cavity. Therefore, dialysate/serum ratios of several complement factors 
were measured in the present study. During CAPD, proteins are lost in the dialysate. The 
amount is related to a number of factors [11-21]. Some of these factors are important for 
all proteins, for example, serum concentration, dwell time, peritoneal permeability, 
dialysate osmolarity, and clinical condition. Others are related to properties of the protein 
itself, such as molecular weight, configuration and charge. The relationship between 
molecular weight and clearance of proteins during CAPD can be described by a power fit 
[17]. This means that the relation between dialysate/serum ratio and molecular weight is 
linear, when plotted on a doublelogarithmic scale. High correlation coefficients for this 
relation were found in all patients in this study, confirming that the relationship is in fact 
linear. Other characteristics of the molecule, such as configuration and charge, were 
neglected in our study, simply because data concerning these matters are only scarcely 
available for a limited number of complement factors. 
The ratios of D and C3d were elevated, whereas those of C3, C4, and Ρ were decreased. 
Relatively low levels of C3, C4 and Ρ could be caused by intraperitoneal consumption of 
complement. The increased levels of C3d support this hypothesis. It cannot be excluded 
that there is also production of these factors in the peritoneal cavity. In that case, 
consumption apparently exceeds production. High dialysate/serum ratios of factor D 
strongly suggest intraperitoneal production. In fact, production of factor D cannot be 
exceeded by consumption because this factor, as opposed to the other factors, is not 
consumed during complement activation [22]. Peritoneal macrophages are probable sites 
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of synthesis [23]. The large standard deviation may be caused by the fact that the stimulus 
for production differs between patients. 
These data provide evidence for activation of complement in the peritoneal cavity in 
children treated with CAPD without peritonitis. Low dialysate/serum ratios of C4 indicate 
activation of the classical pathway, whereas high ratios of factor D and low ratios of factor 
Ρ indicate activation of the alternative pathway. Activation of both pathways of 
complement in the peritoneal cavity could explain raised serum levels of high molecular 
weight complement factors in CAPD patients. Since high levels of factor Ρ were also 
found in preterminal renal failure, CAPD as such is probably not the only factor causing 
complement activation. 
A correlation between opsonic activity of peritoneal dialysis effluent and dialysate C3 
levels has been found in different studies [9,24]. Activation of complement in the 
peritoneal cavity, resulting in a decrease of already low dialysate levels of complement 
factors, may be an important factor promoting the chances for peritonitis. Another possible 
consequence of complement activation is augmentation of protein loss [25]. 
Since activation of complement may have consequences, it is important to know why 
complement is activated in the peritoneal cavity in patients without a clinical peritonitis. 
Interleukin-6 was produced in stable CAPD patients without infection [26]. Maybe 
complement activation and interleukin-6 production have a mutual cause. Of course, it is 
possible that the indwelling catheter or the dialysis fluid are of importance, as suggested 
by Lewis et al. [1]. In that case, activation of the alternative pathway would be the most 
probable route, although extracorporeal circuits, for instance can also activate the classical 
pathway [27]. The levels of factor D in dialysate are very high, with a mean of 40.1 U/ml. 
In normal controls, the mean serum factor D level was only 6.2 U/ml [3]. High levels are 
a consequence of a combination of decreased renal elimination and intraperitoneal 
production. High levels of factor D, as such may lead to alternative pathway complement 
activation [28,29]. Because the classical pathway seems to be involved in the patients we 
studied, the possible presence of antigen-antibody complexes is implicated. Their presence 
would be compatible with chronic low-grade bacterial contamination. A decrease in the 
levels of IgG, C3, and opsonic activity with length of time of CAPD was found by 
different investigators [8,30]. This decrease does not seem to be related to changes in 
membrane permeability [30]. Complement activation occurring later in the course of 
CAPD would be a possibility. Since all children in this study group, with the exception 
of one, had been on CAPD for a period of 5 months or longer, it was not possible to 
differentiate for length of CAPD treatment. 
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It can be concluded from the present study that there is evidence for activation of 
complement in the peritoneal cavity of children on CAPD. The cause of this and the 
consequences are not known. The decrease of already low levels of complement factors 
in dialysate as a result of complement activation may impair host defense. Further research 
to elucidate cause and effect of complement activation in CAPD patients is necessary. 
Appendix 
For each individual к and the four non-complement proteins i, the regression line of log10[R] and 
log,0[W] was fitted: Y=a+bX, where Y is the log10[R] en X is the log10[W]. Let Ym be the measured 
log10[R] of a complement factor for individual к and Yp the predicted log,0[R]. Let d=Ym—Yp. The 
variance of d is the sum of the variances of Y
m
 and Y
c
. The variance of Y
m
 was assumed to be the 
same for all complement proteins and equal to σ2, the variance in the determination of the non-
complement proteins, which can be estimated by the residual error of the least squares regression 
with 2 degrees of freedom. The variance of Y
c
 can be calculated with the following formula [31]: 
o4±HX
m
-X)2lUx
r
X)2) 
П ι 
where: n=4 (number of non-complement proteins); X„, is the log10[W] of the complement factor; X 
is the mean log,0[W] of the non-complement proteins; and X, the log,0[W] of non-complement 
protein i. 
Let d = — Σ<£, then valid) = Hvaiid¿), where dk is the deviance d of individual k. Then 
14 * 142 к 
has a t-distribution with 2x14=28 degrees of freedom. 
\Jvar(d) 
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CAPD is preferred over haemodialysis as a renal replacement therapy in young children 
with chronic renal failure. This thesis presents the results of several clinical studies, 
performed in children treated with CAPD. Transport of fluid and macromolecules from 
the peritoneal cavity to the blood and from the blood to the peritoneal cavity was an 
important issue in most of these studies. 
A general overview is given in chapter 1, with special attention to those aspects of 
CAPD that are studied. A major part of the chapter gives a review on the current 
knowledge of fluid kinetics during CAPD. Net transport of fluid from the blood to the 
peritoneal cavity during CAPD is called ultrafiltration. Ultrafiltration equals the difference 
between osmotically driven water transport into the cavity, called transcapillary 
ultrafiltration, and fluid loss from the cavity, caused by lymphatic absorption. Subdia-
phragmatic lymphatics, that pump fluid out of the peritoneal cavity in conjunction with 
respiratory movement, and intratissue lymphatics draining the tissues surrounding the 
peritoneal cavity, together account for total lymphatic uptake. Lymphatic absorption can 
be estimated from the disappearance of intraperitoneally administered macromolecules. 
This so-called marker clearance is the best available method to estimate lymphatic 
absorption in the clinical setting. Chapter 1 also gives a review on the current experience 
with the treatment of renal anaemia with recombinant human erythropoietin. In children 
treated with CAPD the hormone is usually administered subcutaneously. In fact, this seems 
the most favourable route with respect to dosage. Intraperitoneal administration would be 
preferable, because it abolishes the necessity of frequent injections. In adults the hormone 
has been administered intraperitoneally with success, but no data are available for children. 
Finally chapter 1 describes the known effects of CAPD on the complement system. The 
complement system is important for host defense in the peritoneal cavity. Serum proteins, 
such as complement factors, are lost during CAPD with the dialysate. Although this could 
theoretically lead to deficiencies of complement, this has never been found in adults. In 
children treated with CAPD no information is available concerning the complement 
system. 
Fluid kinetics were studied with different volume markers in chapters 2, 3 and 4. The 
only previous study concerning fluid kinetics in children on CAPD has been performed 
by Mactier et al. [1]. In this study and the studies presented in this thesis, a dwell volume 
was used of 40 ml/kg, which is the usual dwell volume used in the clinical setting. Mactier 
et al. established a mean marker clearance of 469 ml/1.73 m2 during a 4-hour dwell in 6 
children treated with CAPD, whereas mean marker clearance was only 311 ml/1.73 m2 in 
10 adults on CAPD [ 1 ]. Transcapillary ultrafiltration was approximately the same in adults 
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albumin autologous Hb dextran 70 
This thesis 
chapter 
dialysate glucose 
dwell period 
MC children (ml/1.73 m2) 
Literature data 
reference 
dialysate glucose 
dwell period 
MC Children (ml/1.73 m2) 
MC Adults (ml/1.73 m2) 
2 
3.86 % 
6hr 
249 ± 173 
[1] 
2.27 % 
4hr 
469 ± 203 
311 ± 197 
3 
1.36% 
4hr 
521 ± 166 
[5] 
1.36 % 
4hr 
382 ± 146 
4 
1.36% 
4hr 
236 ± 101 
[6] 
1.36 % 
4 hr 
340 ± 105 
3.86 % 
4hr 
307 ± 176 
3.86 % 
4hr 
317 ± 93 
Table 1. Results of measurements of marker clearance (MC) [mean ± standard deviation] in 
the present study in comparison to literature data using different volume markers. 
and children. It was concluded that ultrafiltration in children is reduced as a result of a 
higher lymphatic absorption rate. In fact, it had been reported previously that it is difficult 
to achieve sufficient ultrafiltration in young children [2]. A high lymphatic absorption rate 
seemed a reasonable explanation. The results of the measurements of marker clearance in 
the studies presented in chapter 2, 3 and 4 are compared to literature data in Table 1. 
In chapter 2 human albumin was used as tracer substance. The concentration of the 
marker was 15 g per litre dialysis fluid. A 6-hour dwell was studied in 17 children and 
dialysate was used containing 3.86 % glucose. The results of Mactier et al. were not 
confirmed in this study. On the contrary, in comparison to the adults studied by Mactier 
et al., marker clearance in relation to body weight and initial intraperitoneal volume was 
lower in these children, especially if the fact that a 6-hour dwell was studied is taken into 
account. Correction for body surface area is probably more appropriate than correction for 
body weight or initial intraperitoneal volume, because the peritoneal surface area is related 
to body surface area [3]. Therefore, the results of our study presented in chapter 2 were 
recalculated in relation to body surface area in chapter 3, resulting in a mean marker 
clearance of 249 ml/1.73 m2. This is much lower than the mean marker clearance of 469 
ml/1.73 m2 in children reported by Mactier et al. 
An important disadvantage of human albumin as a marker for the study of fluid kinetics 
during CAPD is the fact that endogenous patient albumin enters the peritoneal cavity 
during the dwell period. At the end of a 4-hour dwell with dialysate to which autologous 
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haemoglobin was added albumin concentration was 500 ±150 mg/1, whereas albumin 
concentration was 1075 ± 450 mg/1 at the end of an overnight dwell (unpublished 
information from the studies described in chapter 3 and 8). We used albumin from the 
central laboratory of the Netherlands Red Cross Blood Transfusion Service. Struijk et al. 
compared the effects of intraperitoneal administration of this brand of human albumin, to 
intraperitoneal administration of albumin produced by another firm (Baxter, Thetford, 
Norfolk, UK) [4]. In response to intraperitoneal administration of human albumin 
produced by the central laboratory of the Netherlands Red Cross Blood Transfusion 
Service, the peritoneal transport of small solutes and IgG significantly increased. This was 
attributed to contamination of the product with prekallikrein activator. In our study 
augmentation of peritoneal transport may have increased albumin concentration 
considerably. This may have caused an erroneously low marker clearance. Human albumin 
does not seem to be a suitable marker for the measurement of fluid kinetics during CAPD. 
In chapter 3 fluid kinetics were studied in 9 children with autologous haemoglobin as 
a marker. A 4-hour dwell was studied and dialysate was used containing 1.36 % glucose. 
Fifty ml of haemolysate was added to the dialysate, establishing a haemoglobin 
concentration of 139 + 58 mg/dl. Mean marker clearance was 521 ml/1.73 m2 in this 
study, which is similar to what Mactier et al. found in children. Marker clearance was high 
in comparison to what was established by Krediet et al. in a study of fluid kinetics during 
CAPD, using the same study protocol [5]. They found a mean marker clearance of 382 
ml/1.73 m2 in 16 adults. 
An important theoretical advantage of autologous haemoglobin as a marker for the 
study of fluid kinetics during CAPD is that the substance is not usually present in the 
peritoneal cavity. We also established some major disadvantages. The production is very 
time-consuming and carries the risk of contamination. We checked the sterility of the 
solution and at 2 occasions we had to draw new blood because contamination had 
occurred. Nevertheless, using this procedure no patient developed a peritonitis shortly after 
the study. The haemoglobin solution had to be prepared in a rather simple way, for 
reasons of sterility. As a consequence, the osmolarity of the solution was very low and in 
order to achieve a concentration in dialysate high enough to perform reliable determina-
tions, rather large quantities had to be added. Because of this the mean osmolarity of the 
dialysis solution containing the marker was only 306 mOsml/1, whereas the osmolarity of 
plain dialysate is 347 mOsml/1. Another very important disadvantage of autologous 
haemoglobin was that 4 out of 9 patients indicated abdominal pain during instillation of 
the autologous haemoglobin solution. Studies with a dialysis solution containing 3.86 % 
150 
EXTENSIVE SUMMARY AND PERSPECTIVES FOR THE FUTURE 
glucose were performed in 2 children (unpublished information). In these children marker 
clearance was similar, whereas transcapillary ultrafiltration was much higher, as would be 
expected. In these 2 children, abdominal pain was very severe, and it was decided to 
terminate the study. The fact that patients suffer from pain during instillation of the 
haemoglobin solution is not only very unpleasant for the patient, but it also means that the 
solution might induce an inflammatory reaction in the peritoneum and this might have 
consequences for peritoneal transport. Although this study seemed to confirm that marker 
clearance is higher in children, the results might have been influenced by the marker itself. 
This assumption was confirmed by the study presented in chapter 4. 
In chapter 4 dextran 70 was used for the study of fluid kinetics. Dextran 70 was added 
to the dialysate to a final concentration of approximately 4 g/1. Eleven dwells were studied 
with a dialysis solution containing 1.36 % glucose and 13 dwells were studied with 
dialysate containing 3.86 % glucose. Mean marker clearance was respectively 236 
ml/1.73 m2 and 307 ml/1.73 m2. The results were similar to those of Imholz et al., who 
performed a similar study in 10 adults [6]. Mean transcapillary ultrafiltration was also 
similar to what Imholz et al. found in adults. However, a positive relationship between age 
and transcapillary ultrafiltration was found. This is probably because dwell volume is 
calculated from body weight. 
Calculation of dwell volume from body weight is applied in all the studies concerning 
fluid kinetics during CAPD in children. The reason for this is the fact that dwell volume 
is traditionally calculated from body weight (usually 40 ml/kg) in clinical practice. In 
adults a dwell volume of 2000 ml is common. It has been assumed that a dwell volume 
of 2000 ml/1.73 m2, which would be similar to adults, would not be tolerated in young 
children. A high incidence of hernias was reported in young children treated with CAPD, 
using a dwell volume of 40 ml/kg [7]. A dwell volume related to body surface area, may 
lead to an even higher incidence of this complication. Fischbach et al. measured the intra-
peritoneal pressure in 3 children younger and 3 children older than 1 year [8]. They used 
a dwell volume of 1000 ml/m2 and surprisingly, the intraperitoneal pressure was found to 
be relatively low in the younger children. This suggests that higher dwell volumes, 
calculated from body surface area, may be tolerated. Peritoneal surface area is related to 
body surface area. This means that dwell volume is low in relation to peritoneal surface 
area in young children, when dwell volume is calculated from body weight. As a result, 
equilibration between dialysate and serum occurs sooner and transcapillary ultrafiltration 
will be less. A low transcapillary ultrafiltration in young children may cause ultrafiltration 
failure. 
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In chapter 5 experiences with the treatment of 16 children with erythropoietin 
administered intraperitoneally are described. Erythropoietin was administered 3 times per 
week during a nightly dwell of 10 to 12 hours in 20 ml/kg dialysis fluid, which was half 
the amount normally used by the child. Mean haemoglobin values increased from 4.9 
mmol/1 to 6.2 mmol/1 after 6 months of therapy and the need for blood transfusions was 
completely abolished. Mean dosage was 370 units/kg per week after 6 months and 279 
units/kg per week after 12 months of therapy. 
Dosage is rather high in comparison to subcutaneous administration and this has 
significant financial implications [9]. In children mean maintenance dose was between 74 
[10] and 210 [11] units/kg per week, when erythropoietin was administered subcu-
taneously. The dose used in the study presented in chapter 5 does not seem extremely 
high, when age is taken into account. The median age of the children was 4.1 years. 
Scigalla et al. published results of a multicentre study of children treated with 
haemodialysis, in whom erythropoietin was administered intravenously. The maintenance 
dose was 321 units/kg per week in the youngest age group (< 5 years) and only 136 U/kg 
per week in the oldest age group (> 15 years) [12]. The cause of this age-dependency of 
need of erythropoietin is unknown. 
The incidence of peritonitis did not increase, when we started to treat the patients with 
erythropoietin intraperitoneally. Nevertheless, every time erythropoietin is injected into a 
dialysis bag, there is a risk of introduction of bacteria. Another disadvantage of intraperito-
neal administration of erythropoietin in the way described, is the fact that 3 times per 
week dialysis is less efficient during the night, because dwell volume is less. For these 
reasons we performed a study in 6 children who had been successfully treated with 
erythropoietin intraperitoneally 3 times per week [13]. In these children erythropoietin was 
administered in the same weekly dose, once a week instead of 3 times per week. This was 
not effective, since haemoglobin levels started to decrease rapidly. 
In chapter 6 a pharmacokinetic study, comparing 3 modes of erythropoietin administra-
tion is presented. Subcutaneous administration is compared to 2 different types of 
intraperitoneal administration. When erythropoietin was administered in 20 ml/kg of 
dialysate (the same way as in the therapeutic study described in chapter 5), the median 
area under the curve was significantly lower, when compared to subcutaneous administra-
tion of the same dose. When erythropoietin was administered in 50 ml of dialysate, 
irrespective of body weight, the area under the curve was similar to subcutaneous 
administration. From this study it can be concluded that, in terms of bioavailability, 
administration of erythropoietin intraperitoneally in a small volume is more effective. 
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In chapter 7 serum levels of complement factors and results of functional assays of 
complement in children treated with CAPD are compared to normal controls and to 
children with preterminal renal failure, conservatively treated. There were no deficiencies 
of complement in serum due to loss of complement factors with the dialysate. Levels of 
factors Clq, C4, C3d, D and P, were higher in the CAPD group in comparison to the 
normal control group. Factors D and Ρ were also elevated in the preterminal group. High 
levels of C3d and D could be explained by reduction of their elimination by the kidney. 
High levels of the other factors were presumed to be caused by an increased synthesis. 
Since levels of factor Ρ were also elevated in the patients with chronic renal failure, who 
were not treated with CAPD, it did not seem that CAPD as such was the only cause. 
In chapter 8 serum and dialysate levels of complement factors were simultaneously 
measured to see if dialysate levels are out of range in relation to their serum levels, 
indicating production or consumption of complement factors in the peritoneal cavity. 
Dialysate/serum ratio's of factor D and C3d were elevated, whereas those of C3, C4 and 
factor Ρ were decreased. These results indicate activation of both pathways of complement 
in the peritoneal cavity in children treated with CAPD without peritonitis. It is not clear 
why complement is activated. Possibly the indwelling catheter is of importance or the 
dialysis fluid. Another possibility is that high levels of factor D, a consequence of 
decreased renal elimination, cause complement activation. Since the classical pathway is 
also activated, antigen-antibody complexes could play a role. Chronic low grade bacterial 
contamination is a possibility. 
Perspectives for the future 
In order to facilitate comparison of data future studies on peritoneal fluid kinetics 
should be standardized for a number of factors. Dextran 70 should be used as a volume 
marker. Since differences in transcapillary ultrafiltration become most obvious when 
dialysate is used with a high glucose concentration, we believe that dialysate should be 
used with 3.86 % glucose. During CAPD, dialysis fluid is usually exchanged 4 times per 
day, with dwell periods of approximately 6 hours. Therefore, a study dwell of 6 hours 
seems a logical choice. It is almost impossible to study 6 hour dwells in an outpatient 
clinic in these patients, who often have to travel several hours to reach the hospital. For 
practical reasons we therefore prefer to study dwell periods of 4 hours. Results should be 
expressed in relation to body surface area. This is also important in studies in adult 
patients, because not all adults have a body surface area of 1.73 m2. 
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We established a relation between age and transcapillary ultrafiltration, and this was 
attributed to the fact that dwell volume is related to body weight. To confirm this studies 
should be performed with dwell volumes calculated from body surface area. Kohaut et al. 
recently advised to use dwell volumes of 1200 mL/m2 when urea and glucose equilibration 
studies are being done to compare individuals of different ages and sizes [14]. This advise 
can also be applied to studies concerning fluid kinetics. It is possible of course, that higher 
intraperitoneal volumes in such a study, will give rise to an increased marker clearance 
[15]. It will be interesting to see what the effect will be on net ultrafiltration. Further 
investigations should also look into the possibility and the necessity of using a dwell 
volume related to body surface area for the daily care of children treated with CAPD. 
It is important that very young children are included in future studies. Almost no data 
are available of children below the age of one year. This is not easy, because studies can 
be performed only if patients are under treatment, and fortunately only very few young 
children are treated with CAPD. In small children, with small dwell volumes, sample 
volume must be minimal. 
Intraperitoneal pressure measurements should be performed in children of different ages 
treated with CAPD to see if there is a relation between age and intraperitoneal pressure. 
It is questionable if measurements of intraperitoneal pressure during CAPD can be used 
to estimate which dwell volume can be tolerated in an individual patient. Measurements 
of intraperitoneal pressure during CAPD are usually performed during rather unphysiolo-
gical situations. Although this cannot be achieved easily, pressure measurements during 
normal activities are preferable. 
If it is feasible to increase dwell volume, because higher volumes are tolerated, this has 
significant implications for the amount of dialysis administered to the patient. The 
consequences of this are uncertain, because it is not known how much dialysis is necessary 
in an individual patient. In adults adequacy of peritoneal dialysis is determined by the 
weekly clearances of urea or creatinine, corrected for the distribution volume (Kt/V). In 
children mean Kt/V was reported to be higher than adults [16]. Studies should be 
performed establishing guidelines for Kt/V for children of different ages. 
We have established that intraperitoneal administration of erythropoietin is effective. 
Future studies should address measures to reduce dose and ways to minimise peritonitis 
risk. To begin with, therapeutic studies will have to establish the dose needed to treat renal 
anaemia with erythropoietin administered intraperitoneally in a small amount of fluid. If 
erythropoietin is administered 3 times per week in 50 ml of dialysis fluid during the night, 
the child will not be dialysed during that time. Maybe adaptations of the dialysis 
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prescription will be necessary. CCPD during the night, with administration of erythropoie-
tin during the day may be a solution. In this respect it is again important to know how 
much dialysis is necessary. 
Since we have established that intraperitoneal administration is an effective method to 
give erythropoietin to a patient treated with CAPD, it would be interesting to try other 
drugs. An example would be growth hormone. Fine et al. have already established that this 
hormone is also resorbed from the peritoneal cavity of children treated with CAPD [17]. 
Preliminary results of a therapeutic study were recently published, indicating that intraperi-
toneal administration of recombinant human growth hormone may be an effective therapy 
for the short stature associated with chronic renal failure [18]. 
Substances are lost from the body with the dialysis solution. We have established that 
this does not cause a deficiency of complement. It should be investigated if loss of other 
substances, such as vitamins or trace elements, causes deficiencies in children treated with 
CAPD. 
In chapter 8 actual dialysate levels of complement factors were appraised in relation to 
their serum concentration, assuming that the main determinant of the dialysate concentra-
tion of a substance is molecular weight, if it is not produced or consumed in the peritoneal 
cavity. This method to establish intraperitoneal production and loss of proteins can also 
be applied to other systems than the complement system. An example would be the 
fibrinolytic system. Fibrin can obstruct the CAPD catheter and formation of fibrin is 
thought to be of importance in the pathogenesis of some forms of peritonitis during 
CAPD. A relative deficiency of factors that promote fibrinolysis in the peritoneal cavity 
during peritonitis could be the cause. Simultaneous measurements of serum and dialysate 
levels of factors that promote and repress fibrinolysis may help us to understand this. 
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SAMENVATTING 
In dit proefschrift worden de resultaten beschreven van enkele studies die verricht werden 
bij kinderen die behandeld worden met continue ambulante peritoneaaldialyse. Continue 
ambulante peritoneaaldialyse, ofwel kortweg CAPD, is een nierfunctievervangende 
behandeling, die sinds ongeveer 15 jaar wordt toegepast bij kinderen. Deze behandeling 
wordt, naast hemodialyse, toegepast bij patiënten waarvan de nieren onvoldoende werken. 
Tijdens deze behandeling wordt via een speciaal daarvoor ingebrachte catheter vloeistof 
(dialysaat) in de vrije buikholte gebracht. Afvalstoffen passeren de peritoneaalmembraan 
en komen in het dialysaat terecht. Vier maal per dag wordt de vloeistof vernieuwd. De 
peritoneaaldialyse vindt dus continu plaats en omdat de patiënt ondertussen kan doorgaan 
met zijn normale dagelijkse activiteiten, wordt gesproken van continue ambulante 
peritoneaaldialyse. 
Hoofdstuk 1 vormt een algemene introductie tot het onderwerp. Ten eerste wordt 
ingegaan op chronische nierinsufficiëntie in het algemeen, op de geschiedenis van de 
peritoneaaldialyse en op de toepassing van CAPD bij kinderen. Vervolgens worden een 
aantal aspecten van CAPD, die in dit proefschrift onderzocht worden, uitgediept. 
Het eerste aspect dat besproken wordt is het transport van vloeistof van en naar de 
buikholte tijdens CAPD. Tijdens CAPD kan vloeistof aan het lichaam worden onttrokken. 
Dit wordt ultrafiltratie genoemd. Ultrafiltratie is het verschil tussen het transport van 
vloeistof van bloed naar buikholte ten gevolge van osmose, de zogenaamde transcapillaire 
ultrafiltratie (TCUF), en het verdwijnen van vloeistof uit de buikholte door lymfatische 
absorptie (LA). De TCUF kan beïnvloed worden door de glucoseconcentratie van het 
dialysaat te variëren. Door verhoging van de glucoseconcentratie kan indien nodig extra 
vocht aan een patiënt worden onttrokken. Lymfatische absorptie leidt tot verlies van ultra-
filtratie. Er kan ook gebruik worden gemaakt van de LA. Indien medicamenten in de 
buikholte worden toegediend, dan worden ze door LA in het lichaam opgenomen. De LA 
kan op verschillende manieren gemeten worden. In de kliniek kan men een indruk krijgen 
van de LA door een molecuul met een molecuulgewicht groter dan 40.000 Dalton, een 
markermolecuul, aan de spoelvloeistof toe te voegen en de klaring van deze marker te 
meten. Deze markerklaring (MK) is dus een benadering van de totale hoeveelheid vloeistof 
die door LA uit de buikholte verdwijnt. In de literatuur wordt melding gemaakt van het 
feit dat het bij jonge kinderen dikwijls moeilijk is om voldoende vocht te onttrekken aan 
het lichaam. Dit zou het gevolg kunnen zijn van een relatief geringe TCUF of van een 
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relatief hoge LA. In de enige studie in de literatuur betreffende het vloeistoftransport bij 
kinderen die behandeld worden met CAPD werd met behulp van albumine als marker een 
hoge MK gevonden ten opzichte van volwassenen. 
In hoofdstuk 1 wordt tevens een overzicht gegeven van de toepassing van erythropoieti-
ne bij de behandeling van anemie bij patiënten met een chronische nierinsufficïentie. Een 
tekort aan dit hormoon, dat door de nieren geproduceerd wordt, is de belangrijkste oorzaak 
van anemie bij patiënten met een chronisch nierlijden. De meest efficiënte manier om het 
hormoon toe te dienen is door middel van subcutane injecties. Het toevoegen van het 
hormoon aan de spoelvloeistof, zogenaamde intraperitoneale toediening, is een alternatief. 
Het voornaamste voordeel hiervan is het feit dat men op die manier de patiënt een aantal 
injecties kan besparen. Alhoewel dit uiteraard bij kinderen een groot voordeel biedt, zijn 
er in de literatuur nog vrijwel geen gegevens bekend over de effectiviteit van intraperitone-
ale toediening van erythropoietine bij kinderen. 
Tenslotte wordt in hoofdstuk 1 een samenvatting gegeven van datgene dat bekend is 
over de invloed van CAPD op het zogenaamde complementsysteem. Het complementsys-
teem bestaat uit een groot aantal eiwitten die een rol spelen bij de afweer. Tijdens CAPD 
gaan eiwitten verloren via de spoelvloeistof. Dit verlies zou kunnen leiden tot een tekort 
aan complementfactoren. Hierover is bij kinderen niets bekend. 
In hoofdstuk 2, 3 en 4 wordt het vloeistoftransport tijdens CAPD bij kinderen bestu-
deerd met behulp van verschillende markers. Er wordt bij deze studies steeds gebruik 
gemaakt van een spoelvolume van 40 mL/kg, het spoelvolume dat ook gebruikt wordt 
tijdens de normale dagelijkse behandeling van deze patiënten. De gegevens worden 
vergeleken met literatuurgegevens, nadat ze gecorrigeerd zijn voor het lichaamsoppervlak 
van de patiënt, berekend uit lengte en gewicht. De reden hiervoor is het feit dat het 
oppervlak van de peritoneaalmembraan evenredig is met het lichaamsoppervlak. 
In hoofdstuk 2 worden de resultaten beschreven van een studie bij 17 patiënten waarbij 
humaan albumine gebruikt is als marker. De resultaten laten een TCUF en een MK zien 
die ongeveer gelijk is aan die bij volwassenen. Albumine is echter geen ideale marker, met 
name omdat albumine uit het bloed van de patiënt zelf tijdens het spoelen in de buikholte 
terechtkomt en de metingen beïnvloedt. 
In de studie beschreven in hoofdstuk 3 is autoloog hemoglobine, dat wil zeggen een 
hemoglobine oplossing bereid uit het bloed van de patiënt zelf, gebruikt als marker. Bij 
9 patiënten werd met behulp van deze marker een zeer hoge MK gevonden. Ook deze 
marker heeft echter een aantal nadelen. De produktie is niet eenvoudig en er bestaat een 
kans op bacteriële besmetting van de marker oplossing. Doordat het eiwit zich in een vrij 
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groot volume bevindt verandert de samenstelling van het dialysaat aanzienlijk. Bij een 
groot aantal patiënten ontstaat verder buikpijn na intraperitoneale toediening van spoel-
vloeistof waaraan autoloog hemoglobine is toegevoegd. Het is uit het bovenstaande 
duidelijk dat het zeker niet uitgesloten is dat het vloeistoftransport beïnvloed wordt door 
toevoeging van autoloog hemoglobine aan het dialysaat. 
In hoofdstuk 3 wordt tenslotte dextraan 70 gebruikt als marker. Dextraan 70 is een 
glucosepolymeer met een gemiddeld molecuulgewicht van 70.000 Dalton. Bij 11 patiënten 
werd het vloeistoftransport bestudeerd bij gebruik van spoelvloeistof met een lage glucose-
concentratie en bij 13 patiënten bij gebruik van spoelvloeistof met een hoge gluco-
seconcentratie. De resultaten voor TCUF en MK waren ongeveer gelijk aan die bij 
volwassenen. Er werd echter een positieve relatie gevonden tussen leeftijd en TCUF. Dit 
kan mogelijk verklaard worden door het feit dat het spoelvolume berekend wordt aan de 
hand van het lichaamsgewicht. Zoals eerder al werd vermeld, is het oppervlak van de 
peritoneaalmembraan gerelateerd aan het lichaamsoppervlak. Kleine kinderen hebben een 
relatief groot lichaamsoppervlak ten opzichte van het lichaamsgewicht. Bij kleine kinderen 
is het spoelvolume dus gering ten opzichte van het oppervlak van de pritoneaalmembraan. 
Daardoor is de osmotische gradiënt tussen bloed en dialysaat sneller verdwenen, waardoor 
de TCUF geringer is. 
In hoofdstuk 5 worden de resultaten beschreven van de behandeling van 16 kinderen 
met intraperitoneaal toegediend erythropoietine. Tijdens deze behandeling werd erythro-
poietine 3 maal per week intraperitoneaal toegediend, toegevoegd aan de helft van de 
normaliter gebruikte hoeveelheid spoelvloeistof. Deze vorm van behandeling van renale 
anemie bleek succesvol. Afgezien van een stijgen van het hemoglobinegehalte, was een 
belangrijk positief aspect van de behandeling het feit dat er geen bloedtransfusies meer 
nodig waren. Wel was er een relatief hoge dosering nodig ten opzichte van subcutane 
toediening. 
In hoofdstuk 6 worden de resultaten gegeven van een farmacokinetische studie. In deze 
studie wordt het verloop van de erythropoietine spiegels in het bloed gemeten na subcutane 
en intraperitoneale toediening. Het oppervlak onder de curve, hetgeen een maat is voor de 
hoeveelheid erythropoietine die door het lichaam wordt opgenomen, blijkt na intraperi-
toneale toediening vergelijkbaar te zijn met subcutane toediening, mits gebruik gemaakt 
wordt van een klein volume spoelvloeistof. Er kan geconcludeerd worden dat toediening 
van erythropoietine in een klein volume de dosering op een gunstige manier zou kunnen 
beïnvloeden. 
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Verlies van complementfactoren met de spoelvloeistof tijdens CAPD zou kunnen leiden 
tot een tekort aan deze factoren in het bloed. In hoofdstuk 7 worden de resultaten 
beschreven van een studie, waarin de serumspiegels van enkele complementfactoren en de 
complementactiviteit bij kinderen die behandeld worden met CAPD gemeten is. De 
resultaten worden vergeleken met die van gezonde controles en van patiënten met een 
nierinsufficièntie die nog niet behandeld worden met een nierfunctievervangende therapie. 
Er werden geen deficiënties aangetoond bij CAPD patiënten. Integendeel, van een aantal 
factoren (Clq, C4, C3d, D en P) was de spiegel juist hoog. Bij de factoren D en C3d, 
factoren met een klein molecuulgewicht, kan dit verklaard worden door het feit dat deze 
moleculen bij patiënten met een nierinsufficièntie minder goed uit het lichaam verwijderd 
worden. Voor de hoge serumspiegels van enkele factoren met een groot molecuulgewicht 
(Clq, C4 en P) bij patiënten behandeld met CAPD werd geen goede verklaring gevonden. 
Aangezien de spiegel van factor Ρ ook hoog was bij patiënten met een nierinsufficièntie, 
die nog niet behandeld waren met CAPD, leek CAPD niet (de enige) oorzaak. 
Behandeling van patiënten met CAPD zou kunnen leiden tot een activatie van het 
complementsysteem in de buikholte, met als gevolg extra aanmaak van complementfacto-
ren. In hoofdstuk 8 worden de resultaten gegeven van een studie waarbij de dialysaatspie-
gels en serumspiegels van enkele complementfactoren tegelijkertijd gemeten zijn. De 
dialysaat/serum ratio's van deze factoren werden vervolgens vergeleken met de ratio's van 
enkele andere eiwitten met een vergelijkbaar molecuulgewicht. Uit dit onderzoek bleek dat 
de ratio's van een aantal complementfactoren (D en C3d) hoger waren dan verwacht, 
terwijl de ratio's van een aantal andere factoren (C3, C4 en P) lager waren dan verwacht. 
Deze gegevens duiden op een activatie van het complementsysteem in de peritoneaalholte. 
In hoofdstuk 9 worden de resultaten samengevat en worden tevens suggesties gedaan 
voor onderzoek in de toekomst. 
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NOTES 
STELLINGEN 
Behorend bij het proefschrift 
CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 
IN CHILDREN 
- transport studies -
R.E. Reddingius 
1. Ter voorkoming van misverstanden is het verstandig om te spreken van 
markerklaring en niet van lymfatische absorptie, indien de lymfatische 
absorptie tijdens continue ambulante perititoneaaldialyse wordt bepaald 
middels de zogenaamde "tracer disappearance" methode (Hoofdstuk 3). 
2. Indien bij jonge kinderen die behandeld worden met continue ambu-
lante peritoneaaldialyse gebruik gemaakt wordt van een spoelvolume 
van 40 mL/kg, dan dient dit spoelvolume te worden verhoogd als het 
moeilijk blijkt te zijn om voldoende vocht aan het lichaam te onttrek-
ken (Hoofdstuk 4). 
3. Bij kinderen die behandeld worden met continue ambulante peritone-
aaldialyse heeft, bij de behandeling van renale anemie, intraperitoneale 
toediening van erythropoietine de voorkeur boven subcutane toediening 
(Hoofdstuk 5). 
4. Het verlies van complementfactoren met de spoelvloeistof bij kinderen 
die behandeld worden met continue ambulante peritoneaaldialyse leidt 
niet tot een tekort in het bloed (Hoofdstuk 7). 
5. Als er bij kinderen, behandeld met continue ambulante peritoneaal-
dialyse, géén duidelijke klinische problemen zijn, dan wordt gebruik 
gemaakt van een standaard spoelschema. De hoeveelheid dialyse die 
een patiënt krijgt zou echter beter afgestemd moeten worden aan de 
behoefte (T.L.M. Walk et al. Pediatr Nephrol 1994; 8:C47A). 
6. Bij continue ambulante peritoneaaldialyse van kinderen vormen niet de 
uitvoerende aspecten van en de medische verantwoordelijkheid voor de 
behandeling de zwaarste belasting voor de ouders, maar psychische 
factoren zoals onzekerheid over de toekomst van het kind en over de 
resultaten van een transplantatie (G.M. Hulstijn-Dirkmaat et al. Acta 
Paediatr 1994; 83:972-8). 
7. Bij studies betreffende vloeistoftransport tijdens continue ambulante 
peritoneaaldialyse zou men ook de intraperitoneale druk en de houding 
van de patiënt moeten betrekken (A.L.T. Imholz et al. Kidney Int 
1993; 44:1078-85). 
8. Bij het spreken met een patiënt met een kwaadaardige ziekte moet het 
woord kanker uitgesproken worden. Dat wil niet zeggen dat men dat 
bij de eerste de beste gelegenheid moet doen (D.J.Th. Wagener Ned 
Τ Geneeskd 1995; 139:85-9). 
9. Het bijwonen van de rouwplechtigheid van een overleden chronisch 
ziek kind door medisch personeel dat nauw bij de behandeling was 
betrokken is een grote steun voor de nabestaanden en behoort dus in 
principe tot de taken van dat personeel. 
10. Voordat men tot een beenmergtransplantatie overgaat bij een congeni-
tale thrombocytopenic, dient men eerst onderzoek naar het effect van 
thrombopoietine af te wachten. 
11. Endocriene overactiviteit kan behalve op een overmaat aan hormoon 
ook berusten op een genetische mutatie die de hormoonreceptor 
blijvend activeert (L. Duprez et al. Nature Genet 1994; 7:396-401). 
12. Indien voor en nadelen tegen elkaar moeten worden afgewogen, dan 
zullen die zaken die het best gekwantificeerd kunnen worden, in het 
algemeen het zwaarste wegen. 
13. Het is, gezien de enorme technologische vooruitgang van de afgelopen 
jaren, verwonderlijk dat de duurzaamheid van fietsverlichting nog 
zoveel te wensen overlaat. 
14. Niet alleen het veranderen van tekstverwerker, maar ook het overstap-
pen naar een nieuwere versie van dezelfde tekstverwerker tijdens het 
verrichten van een promotieonderzoek is onverstandig. 
15. Bij krapte aan personeel bij de behandeling van ernstig zieke kinderen 
wordt in het algemeen te weinig geluisterd naar de stem van het hart 
en te veel naar restrictieve regelgeving (R.E. Reddingius, C.H. 
Schröder, L.A.H. Monnens). 
Nijmegen, 15 Mei 1995 



